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COMMENT

THE ELIMINATION OF PROCESS: WILL THE
BIOTECHNOLOGY PATENT PROTECTION
ACT REVIVE PROCESS PATENTS?
I.

INTRODUCTION

With the encouragement of George Washington and Thomas
Jefferson, Congress enacted the first patent act on April 19, 1790.1
For two hundred years the patent system has been an important
means of encouraging the advancement of the sciences. 2 However,
due in part to the success of the patent laws in achieving this end,
new technologies have emerged that may not "fit into" the patent
code. One of these is biotechnology.
1. H. TOULMIN, JR., INVENTION & THE LAw 10-11 (1936). On July 31 of the
same year, the Commission for the Promotion of Useful Arts issued its first
patent to Samuel Hopkins of Vermont for a process of making potash and pearl
ash. Secretary of State Thomas Jefferson, an inventor himself, together with
the Secretary of the Department of War and the Attorney General, formed the
Commission. Graham v. John Deere Co., 383 U.S. 1, 6-7 (1966). Any two of
these individuals could issue a patent. Id. at 7. Eventually, this function became too burdensome in combination with the officers' other duties, and the
judiciary assumed the responsibility of issuing patents. Id. at 10.
2. Mr. Toulmin praises the United States' enlightened patent system for
paving the road to America's success in industry. H. TOULMIN, JR., HANDBOOK
OF PATENTS 4 (1949). Toulmin agreed with Abraham Lincoln, recipient of U.S.
Patent No. 6,649 for 'A Device for Buoying Vessels over Shoals,' who said, "The
patent system added the fuel of interest to the fire of genius." Id. at 31 n.39, iii.
A solid patent system is a "highly significant component" of technological advancement. Adler, Biotechnology Development and Transfer: Recommendations for an Integrated Policy, 11 RUTGERS COMPUTER & TECH. L.J. 464, 478
(1985). "Whether respondent's claims are patentable may determine whether
research efforts are accelerated by the hope of reward or slowed by want of
incentives .... " Diamond v. Chakrabarty, 447 U.S. 303, 317 (1980); see generally
C. JuMA, THE GENE HUNTERS: BIOTECHNOLOGY AND THE SCRAMBLE FOR SEEDS,
149-78 (1989) (analyzing effect of intellectual property protection on plant technology advancement).
But see Buttel & Belsky, Biotechnology, Plant Breeding, and Intellectual
Property: Social and Ethical Dimensions, 12 SCIENCE TECH. & HUMAN VALUES
31 (1987). In their study of the seed industry, Buttel and Belsky concluded that
while the Patent Act was effective in sparking economic growth (which led to
the formation of U.S. and multinational seed companies), it was less effective in
stimulating research and formation of new seed varieties. Id. at 35. Rather, the
major companies actively discouraged the release of new varieties, which would
mean increased competition. Id.
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Biotechnology is the application of engineering and technological principles to living organisms or their components to produce
new inventions or processes.3 An important branch of biotechnol5
ogy is genetic engineering, 4 or recombinant DNA technology,
which concerns the analysis and alteration of genes and proteins.
These sciences are of vital importance to U.S. and world progress in
6
innumerable fields.
Biotechnology has the potential to eradicate thousands of diseases and feed millions of people. It promises advances to offset
pollution and protect the environment. 7 As an industry it is a remarkable source of revenue, boasting a multi-billion dollar market.8 The recombinant version of the protein erythropoietin
3. See McGRAw HILL DICTIONARY OF SCIENTIFIC TERMS 184 (3d ed. 1984);
Note, Altering Nature's Blueprints for Profit- Patenting Multicellular Animals, 74 VA. L. REV. 1327, 1327 n.3 (1988). Biotechnology subsumes many sciences, such as biochemistry, microbiology, chemical engineering, agronomy, and
applied genetics. Id. Biotechnology research may relate to recombinant DNA
and hybridoma technologies, pharmaceuticals, peptides, antibodies, vaccines,
enzymes, cell lines, media, diagnostic pregnancy and cancer kits, and plant hybrids. Ihnen, Patenting Biotechnology: A Practical Approach, 11 RUTGERS
COMPUTER & TECH. L.J. 407 (1985).
Congress defines a biotechnological material as a "biologically engineered
organism that is essential for the production of a product [and] ... includes any
host cell, DNA sequence, or vector." H.R. 3957, 101st Cong., 2d Sess., 136 CONG.
REC. E207 (1990) (section 2(b)(2) of proposed Biotechnology Patent Protection
Act).
4. Genetic engineering is "the intentional production of new genes and alteration of genomes by the substitution or addition of new genetic material."
MCGRAw HILL DICTIONARY OF SCIENTIFIC AND TECHNICAL TERMS 675 (3d ed.

1984).
5. Recombinant DNA technology is another name for genetic engineering.
Deoxyribonucleic acid (DNA), the "molecule of life," resides on chromosomes
in sequences which are found in the nucleus of every cell of a eucaryotic organism. J. WATSON, J. TooZE & D. KuRTz, RECOMBINANT DNA, A SHORT COURSE

1-2 & 6-8 (1983) [hereinafter RECOMBINANT DNA]. In recombinant DNA technology, DNA, the genetic information, from one species may be "recombined"
with the DNA of another species. Id. at 58-71.
6. See infra notes 7-10 and accompanying text (discussing advances in biotechnology); see also 134 CONG. REC. S8061 & S8064 (daily ed. June 17, 1988)
(statement of Rep. Chiles) (Biotechnology will revolutionize many sectors and
"have enormous impact on the next decades").
7. See Adler, supra note 2. Advances in biotechnology will allow scientists and consumers to tap into the genetically-rich resources of tropical plants
and fauna. Id. at 471. This will help prevent resource reduction caused by gene
depletion. Id.
8. See STATEMENT OF THE INDUSTRIAL BIOTECHNOLOGY ASSOCIATION IN
SUPPORT OF THE BIOTECHNOLOGY PATENT PROTECTION ACT TO THE SUBCOMMITTEE ON COURTS, INTELLECTUAL PROPERTY, AND ADMINISTRATION OF JUSTICE OF
THE HOUSE JUDICIARY COMMITTEE, September 25, 1990 [hereinafter IBA STATE-

MENT] (listed profit and investment figures and noted that biotechnology is one
of the country's most intensive research and development industries). The U.S.
Department of Commerce predicts that the market for biotech-related products
will reach $40 billion by the year 2000. 134 CONG. REC. S8061 (daily ed. June 17,
1988) (statement of Rep. Chiles). The Japanese have estimated the market to
be worth $100 billion by 2000. Id. In 1985, in the U.S., pharmaceutical compa-
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("EPO"), 9 which prevents blood clotting, alone has an estimated
value of $1 billion.10 The United States currently leads the world in
biotechnology innovation and production, but Japan and Germany
are narrowing the gap." The United States cannot afford to lose its
12
edge in yet another technology to its world competitors.
The biotechnology revolution is not unlike the industrial
revolution, which itself spawned countless patents.' 3 Inventors
during the industrial revolution had to overcome hurdles in the patent system to obtain adequate protection. In fact, from as early as
185314 to as late as 1909,15 the United States Supreme Court refused
16
to recognize mechanical processes as patentable subject matter.
nies invested $4.1 billion in research and development; in 1986 they invested
$4.6 billion. Mossinghoff, Research-Based Pharmaceutical Companies: The
Need for Improved PatentProtection Worldwide, J. L. & TECH. 307, 308 (1987).
In 1987, the pharmaceutical industry maintained 36,000 jobs, half of which were
for scientists and engineers. Id. It takes an average of ten years and $125 million to produce a new marketable drug in the United States; see also The Chicago Tribune, Feb. 18, 1990, § 5, at 1 & 13, col. 1 (patented cell line for restoring
white blood cells in treatment of cancer patients worth millions of dollars).
9. EPO is used for treatment of anemia, which is a reduction in the total
quantity of red blood cells in circulation. MCGRAw HILL ENCYCLOPEDIA OF SCIENCE AND TECHNOLOGY 535 (6th ed. 1987). EPO is helpful because it stimulates
the production of red blood cells. Id. at 536.
10. 12 Legal Times, Jan. 8, 1990, at 1, col. 2.
11. Griffen, Exporting Biotechnology: The Pitfalls, 3 AM. INTELL. PROP.
L.A.Q.J. 542, 545 (1988-89).
12. See Corcoran, Science and Business, 262 Sci. AM. 82 (1990) (analyzing
department of defense statistics that show Japan to be "significantly ahead" of
the United States in some aspects of biotechnology, semiconductor and electrical sciences, photonics, superconductivity, and machine intelligence).
13. In 1869, George Westinghouse, Jr., received patent number 88,929 for
his invention of the air brake. H. TOULMIN, supra note 2, at 31 n.39. In 1870,
John and Isaiah Hyatt received a patent for "Improvements in Treating and
Molding Pyroxyline," the foundation for the celluloid industry. Id. In 1873,
patents issued to Louis Pasteur and Eli Janney, respectively, for their inventions of a process of making beer and car couplings. Alexander Graham Bell
obtained a patent for the telephone in 1876. Id. at 32 n.39. In 1878, Thomas
Edison received a patent for a "Phonograph or Speaking Machine," and in 1880
he obtained a patent for his electric lamp; in all Mr. Edison received 1101 patents. Id. This is just a sampling of the break-through inventions patented in
the United States during the industrial revolution. Today, patent applications
are on the rise: 1988 broke the record for patent applications filed, numbering
137,000; 152,000 applications were projected for 1989. Statement of Quigg, 38
PAT. TRADEMARK & COPYRIGHT J., 465, 466 (1989). Unfortunately, the backlog
in patent applications was an average of 19.9 months in 1988; the PTO was
shooting for an eighteen month backlog for 1989. Id.
14. See, e.g., Corning v. Burden, 56 U.S. (15 How.) 252 (1853) (process that is
function of a machine is not patentable).
15. See, e.g., Expanded Metal Co. v. Bradford, 214 U.S. 366 (1909) (process
involving mechanical operations may be patentable).
16. See, e.g., Westinghouse v. Boyden Power Brake Co., 170 U.S. 537 (1898)
(mechanical processes not patentable); Risdon Locomotive Works v. Medart,
158 U.S. 68 (1895) (same).
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By 1935 the Court's approach had softened considerably. 17 Today,
the patent system poses similar obstacles for inventors seeking bi8
otechnological process patents.'

Myriad problems confront biotechnology in the procurement of
protection for its inventions. 19 One problem is that the Patent Code
requires that an invention not be obvious to one of ordinary skill in
the field or science to which the invention pertains. 20 This requirement is troublesome to biotechnology where scientists utilize wellknown processes, indispensable to the invention, to create com-

pletely new products. 2 1 Many of biotechnology's most important
developments, such as insulin, 22 EPO, 23 and tissue plasminogen ac17. See, e.g., Waxham v. Smith, 294 U.S. 20 (1935) (process is not unpatentable merely because it is used in machine).
18. Those in the computer field have experienced the same phenomenon.
See Note, Computer IntellectualPropertyand Conceptual Severance, 103 HARV.
L. REV. 1046 (1990). Currently, patent protection for computer-related inventions is questionable and copyright protection is often inadequate. Id.
19. Judge Young noted that biotech raises issues that "rattle, ostensibly at
least, the traditional foundations of patent law; that is [sic] how do putative proprietary interests in recombinant technology interact with traditional concepts
of patent law?" Amgen, Inc. v. Chugai Pharmaceutical Co., 706 F. Supp. 94, 95
(D. Mass. 1989).
For example, there is no provision in the patent code that specifically addresses the patentability of living organisms. Biotechnology, by definition, concerns the manipulation of living organisms, for which inventors are naturally
seeking patents. See supra note 3 and accompanying text (defining biotechnology). In 1980, the Supreme Court held that living organisms are patentable.
Diamond v. Chakrabarty, 447 U.S. 303 (1980). In Chakrabarty,the Court held
that living organisms are patentable subject matter in accordance with 35 U.S.C.

§ 101. Id.

In 1988, the Patent and Trademark Office issued a patent for a transgenic,
cancer-prone mouse to Philip Leder's laboratory at Harvard. Erickson, supra
note 7, at 102. Strong opposition to patenting living organisms has surfaced
since the United States Supreme Court decided that viability does not preclude
patentability. See generally Sease, From Microbes, to Corn Seeds, to Oysters, to
Mice: Patentabilityof New Life Forms, 38 DRAKE L. REV. 551 (1988-89) (analyzes evolution of case law in granting patents for living organisms and discusses ensuing ethical and legal issues). As a result of Chakrabarty and its
progeny, Congress is considering legislation, namely The Transgenic Animal
Patent Reform Act. H.R. 4970, 99th Congress, 2d Sess., 134 CONG. REC. 7436
(1988).
20. 35 U.S.C. §§ 102-103 (1988). The novelty and nonobvious requirements
are discussed at infra notes 48-49.
21. See infra notes 70-79 and accompanying text (discussing genetic engineering and monoclonal antibody techniques).
22. Insulin is used to treat diabetics. M. STRICKBERGER, GENETICS 167 (3d
ed. 1985). Sugar levels normally controlled by the hormone insulin are not
properly regulated in persons with diabetes. Id. The administration of insulin
will protect diabetics from possible coma and death. Id. at 168.
23. The human kidneys produce EPO, which promotes the production of
red blood cells in the bone marrow. MCGRAw HILL ENCYCLOPEDIA OF SCIENCE
AND TECHNOLOGY 535 (6th ed. 1987). Individuals suffering from anemia-as a
result of kidney disease, cancer, or AIDS---are unable to produce sufficient
amounts of red blood cells. Id. Recombinant EPO ("rEPO") allows for the
manufacture of far greater amounts of the protein than a human normally can
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tivator ("TPA"), 24 are simply recombinant versions of their often
indistinguishable natural counterparts. The present interpretation
of the nonobvious requirement denies inventors, who develop
processes yielding beneficial products, patent protection if the
claimed process is based on a known process. This denial of patent
protection occurs even if the process incorporates new starting
materials or results in a new final product. 25
Currently, U.S. laws inadequately protect patented inventions
from the importation of products manufactured abroad using starting materials patented in the United States. The International
Trade Commission does not have jurisdiction to exclude these infringing products from importation into the United States. 26 The
nonobvious requirement as applied to process patents and the importation of products made from patented starting materials are the
focus of this comment.
In response to the varied problems of applying the patent laws
to biotechnology inventions, Congress has introduced numerous
bills to encourage the advancement and protection of the science
and its related industries. 27 Recently, Congressman Boucher intro2s
If
duced the Biotechnology Patent Protection Act ("BPPA").
passed, the BPPA would accomplish two things: 1) extend patent
produce. Id. The administration of rEPO boosts the patients' red blood cell
production, thereby "vastly improving their lives and in some cases, saving
them." Id.
24. TPA is a drug for heart attack victims: it saves lives by dissolving arterial blood clots quickly. 136 CONG. REc. E213 (daily ed. Feb. 7, 1990) (statement
of Rep. Boucher).
25. See In re Durden, 763 F.2d 1406 (1985). Durden and its progeny are discussed infra notes 109-31 and accompanying text. Courts generally have been
encouraging to the biotechnology industry. See, e.g., Diamond v. Chakrabarty,
447 U.S. 303 (1980) (court overruled PTO rejection and granted patent for living
organism); Armitage, The Emerging U.S. Patent Law for the Protection of Biotechnology Research Results, 2 EUR. INTELL. PROP. REv. 47, 57 (1989) (federal
circuit subscribes to a pro-biotech patent public policy). However, the impetus
has not flowed over to process patents.
26. See, e.g., Amgen, Inc. v. United States Int'l Trade Comm'n, 902 F.2d 1532
(Fed. Cir. 1990). This topic is discussed more thoroughly at infra notes 111-21
and accompanying text.
27. See, e.g., H.R. 4970, 100th Cong., 2d Sess., 134 CONG. REC. H.R.7436-39
(daily ed. Sept. 13, 1988) (addresses legal and policy issues of patenting animals);
1114 Official Gazette 29 (U.S.P.T.O.) (May 15, 1990) (reprinting Patent and
Trademark Office Amendment to Regulations,37 CF.R. PartI: Requirements
for Patent Applications Containing Nucleotide Sequence and/or Amino Acid
Sequence Disclosures); see generally Hoffman, The Biotechnology Revolution
and its Regulatory Evolution, 38 DRAKE L. REv. 471 (1988-89) (author outlines
current issues in biotech and the legislative responses to these issues).
28. U.S. Representative Boucher introduced House Bill H.R. 3957 on February 7, 1990. 136 CONG. REC. E213 (daily ed. Feb. 7, 1990). The stated purpose of
the bill is to eliminate barriers to U.S. biotechnology companies in obtaining
patent rights. Id. at E207 (statement of Sen. Moorhead). The bill will work to
eliminate unfair trade practices which disfavor American biotech companies.
Id. The BPPA states in full:
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Section 1. Patentability of Certain Processes. Section 103 of title 35, United
States Code, is amended by adding at the end the following new paragraph:
"A process of making a product shall not be considered obvious under this
section if an essential material used in the process is novel under section
102 and otherwise nonobvious under section 103."
Section 2. Importation Prohibition; Infringement by Importation, Sale, or
Use.
(a) Amendment to Tariff Act of 1930.-Section 37(a)(1)(B) of the Tariff Act
of 1930 (19 U.S.C. 1337(a)(1)(B) is mended(1) in clause (i) by striking "or" after the semicolon;
(2) in clause (ii) by striking out the period at the end and inserting ";
or"; and
(3) by adding at the end the following:
"(iii) are made, produced, or processed under, or by means of, the uses of a
biotechnological material (as defined under section 154
(b) of title 35;, United States Code) covered by a valid and enforceable
United States patent."
(b) Amendments to Title 35, United States Code.(1) Infringement.--Section 271 of title 35, United States Code, is amended
by adding at the end the following new subsection:
"(h) Whoever without authority imports into the United States or sells
or uses within the United States a product which is made by sing a biotechnological material (as defined under section 154 (b)) which is patented
in the United States shall be liable as an infringer if the importation, sale,
or use of the product occurs during the term of such patent."
(2) Contents and Term of Patent.-Section 154 of title 35, United States
Code, is amended(A) by inserting "(a)" before "Every";
(B) by inserting "(1)" after "in this title";
(C) by striking "and, if the invention" and inserting "(2) if the invention";
(D) by inserting after "products made by that process," the following:
"and (3) if the invention is a biotechnological material used in making a
product, of the right to exclude others from using or selling throughout the
United States, or importing into the United States, that product,"; and
(E) by adding at the end the following:
"(b) For purposes of this section, the term 'biotechnological material'
means a biologically engineered organism that is essential for the production of a product. Such term includes any host cell, DNA sequence, or
vector."
Section 3. Effective Date.
(a) Section 1.-The amendment made by section 1 shall apply to all United
States patents granted before, on, or after the date of the enactment of this
Act and to all applications for United States patents pending on or filed
after such date of enactment, including any application for the reissuance
of a patent.
(b) Section 2.-(1) The amendment made by section 2(a) shall apply only to
articles imported, or sold for importation, on or after the date of the enactment of this Act.
(2)(A) subject to subparagraph (B), the amendments made by section 2(b)
shall take effect on the date of the enactment of this Act.
(B)(i) With respect to any article which is imported before February 6,
1990, and which, but for the amendment made by section 2(b), could be sold
or used within the United States, no person shall be liable for infringement
under section 271(h) of title 35, United States Code, for such sale or use.
(ii) With respect to any article which is imported on or after February 6,
1990, but before the date of the enactment of this Act and which, but for the
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protection to processes 29 where novel and nonobvious 30 starting
materials are used, even if the process itself is otherwise obvious;
and 2) increase protection of U.S. patented starting materials used
31
abroad to make products for importation into the U.S.
The biotechnology industry welcomes these changes.3 2 By increasing patent protection, the Act will provide the incentives necessary to enable biotechnology companies, particularly those
dealing in pharmaceuticals, to commit the required resources for
amendment made by section 2(b), could be sold or used within the United
States, no person shall be liable for infringement under section 271(h) of
title 35, United States Code(I) for the first such sale if it is made within 90 days after the date of the
enactment of this Act; or
(II) for any such subsequent sale or for any such use.
H.R. 3957, 101st Cong., 2d Sess., 136 CONG. REC. E207 (1990).
29. A process patent relates to a method of making an article. Amgen, Inc.
v. Chugai Pharmaceutical Co., 706 F. Supp. 94, 107 (D. Mass. 1989). A product
patent relates to an invented or discovered article. Id. (citing In re Amtorg
Trading Corp., 75 F.2d 826 (3d Cir.), cert. denied sub. nom. International AGR
Corp. v. Amtorg Trading Corp., 296 U.S. 576 (1935). A product patent includes
the right to restrict the use and sale of the product regardless of how and by
whom it was manufactured. Id. A process patent covers only those products
made by the patented process. Id.
30. The terms "novel" and "nonobvious" are defined and discussed at infra
notes 46 & 49 and accompanying text.
31. Recent events in the biotech arena may have spurred this legislative
action. For example, two major pharmaceutical companies-one American, the
other Japanese-have been battling over the rights to the billion dollar drug,
EPO. Amgen, Inc. v. United States Int'l Trade Comm'n, 902 F.2d 1532 (Fed. Cir.
1990); Amgen, Inc. v. Chugai Pharmaceutical Co., 706 F. Supp. 94 (D. Mass.
1989); Amgen, Inc. v. Chugai Pharmaceutical Co., 13 U.S.P.Q.2d (BNA) 1737
(1989); Amgen, Inc. v. Chugai Pharmaceutical Co., 11 U.S.P.Q.2d (BNA) 1466
(1989); In re Certain Recombinant Erythropoietin, 10 U.S.P.Q.2d (BNA) 1906
(1989). The litigation has taken place in the U.S. District Court in Massachusetts, the U.S. International Trade Commission ("ITC"), the Food and Drug Administration, and the PTO. Morgan, On the Political Frontiers of
Biotechnology, Legal Times, Jan. 8, 1990, at 1, col. 2. The litigation between
Amgen, Inc., an American company, and Japan's Chugai Pharmaceutical Company, represents many of the problems facing U.S. companies in the biotech/legal arena.
In the Amgen case, Amgen owns the patent for the starting materials necessary to produce recombinant EPO ("rEPO"), but Genetics Institute owns the
patent (and has licensed it to Chugai) for the purified version of EPO. Amgen,
13 U.S.P.Q.2d (BNA) at 1741. Thus, neither may make EPO or rEPO without
infringing the other's patent. Id. However, companies in these situations usually avoid litigation and enter cross-licensing agreements. Legal Times, Jan. 8,
1990, at 21, col. 4.
32. The Industrial Biotechnology Association ("IBA"), whose members include over a dozen major biotech firms and represent over 80% of the industry's
financial resources, has endorsed the BPPA. IBA STATEMENT, supra note 9, at
1. Genetics Institute is the only IBA member to withold its support. Id. at Table 1. This is probably due to Genetics Institute's stance in its current litigation
with Amgen, Incorporated.
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progress.3 3 The need for uniform standards with predictable applications is manifest. The patent system hinders biotechnology advancement because current inadequacies threaten to defeat
investment incentives and damage American companies' abilities to
34
develop new products.
This comment analyzes the BPPA and the effect it will have on
process patent applications and the importation of certain biotechnological products. Part II discusses the history and background of patent law, biotechnology, and related trade issues. Part
III addresses the current inadequacies of U.S. patent and trade laws
in protecting biotechnology process and starting materials inventions, and appraises the efficacy of the BPPA in resolving these inadequacies. Part IV examines the future of biotechnology and
process patents and proposes alternative solutions to the problems
addressed by the BPPA.
II.

UNITED STATES PATENT AND TRADE LAWS AND THEIR
APPLICATION TO BIOTECHNOLOGY

The United States Constitution grants Congress broad powers
to regulate patents in order to promote the progress of the arts and
science. 35 Under these powers, Congress established the patent sys33. Mossinghoff, supra note 8, at 307. Mossinghoff believes that patent protection is the only effective way to stimulate expansion. Id. He stated that currently incentive is low, and improvement is desperately needed. Id.
34. "[T]he deficiency in current law will severely weaken investment incentives and damage the ability of American companies to create new products."
136 CONG. REC. E213 (daily ed. Feb. 7, 1990) (statement of Rep. Boucher). The
backlog in patent applications averaged 19.9 months in 1988; the PTO was trying
for an 18 month backlog for 1989. Address by PTO Commissioner Donald J.
Quigg to the ABA Conference, reprintedin 38 PAT. TRADEMARK & COPYRIGHT
J. 465, 466 (1989). In addition, patent applications are on the rise: 1988 broke
the record for patent applications filed with 137,000; 152,000 were projected for
1989. Id.
One commentator stated that the patent system is stifling biotech progress.
Adler, supra note 2, at 478-79. Adler, who clerked for Federal Circuit Judge
Rich, stated that even after the breakthrough case of Diamond v. Chakrabarty,
the Patent and Trademark Office has been overly conservative in issuing biotech patents. Id. Adler further admonishes the PTO for demonstrating erroneous judgment and an "unenlightened policy." Id. at 479. The Congress and
the Department of Commerce do not fair much better; in Adler's opinion, they
both are replete with inadequacy and oversight. Id. at 480.
But see Statement of Quigg, 38 PAT. TRADEMARK & COPYRIGHT J. 465, 466
(1989) (discusses improvements in patent law underway at PTO). The PTO has
launched a thirteen-point plan to deal with biotech. Id. There were 100 examiners in the biotech examiners group, and the PTO formed the Biotech Institute
to train examiners. Id. The PTO is concerned with "high quality examination"
as opposed to large quantity turn-over when issuing patents. Id.
35. U.S. CONST. art. I, § 8, cl. 8. This constitutional provision grants Congress the power to regulate laws "[t]o promote the progress of science and useful arts by securing for limited times to authors and inventors the exclusive
right to their respective writings and discoveries." Id. Congress may legislate
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tern whereby the government grants an inventor certain exclusive
rights to his or her invention for a period of time in exchange for
the disclosure of the invention. 36 This reward system is designed to
benefit the public by bringing forth new knowledge and stimulating
37
research.
Title 35 of the United States Code sets forth the requirements
and guidelines for obtaining and enforcing patent rights.38 Today,
an inventor's exclusive right 39 to exclude others from making, us40
ing, and selling the invention extends for seventeen years.
An inventor may obtain a patent in any or all of three categories: the final product obtained, the starting material used, or the
process by which a final product is made or a starting material is
to "best effectuate the Constitutional aims." Graham v. John Deere Co., 383
U.S. 1, 6 (1966). Thus, "Congress may set out conditions and tests for patentability." Id. When interpreting the patent laws, a court should not read in limits
that Congress did not expressly intend. Diamond v. Chakrabarty, 447 U.S. 303,
303-08 (1980) (citing United States v. Dubilier Condenser Corp., 289 U.S. 178, 199
(1933)). The founders of this country recognized the importance of a system to
encourage technological advancement. Graham, 383 U.S. at 5. Thomas Jefferson was a key figure in forging the first patent laws and his principles were
embodied in the 1793 Patent Act. Id. at 7. Jefferson was concerned with achieving a proper balance between the evils of monopoly rights and the bonuses of
incentive to advance science and development. Id. at 9-11.
In 1982, Congress created the United States Court of Appeals for the Federal Circuit. 2 D. CHISUM, PATENTS § 5.02[6] (1989). The Federal Circuit Court
has exclusive jurisdiction over appeals arising under the U.S. patent laws. Id.
Congress' primary goal in creating a federal appellate court for patent cases was
to promote uniformity and predictability in the application of the patent laws.
Id. (citing H.R. 97-312, 97th Cong., 1st Sess., CONG. REC. 20-23 (1981)).
All three branches of government are involved in technology transfer: the
legislature in its power to regulate patents, interstate commerce, and international trade; the president in his treaty-making capacity; and the judiciary in its
power to construe the applicable laws. U.S. CONST. art. I, § 8, cls. 3 & 8; art. II,
§ 2, cl. 2; art. III § 2, cl. 1.
36. Patent laws do not grant exclusive property rights in the patented subject-matter. Armitage, U.S. Patent Law for Biotechnology Research Results, 2
EUR. INTELL. PROP. REV. 47, 56 (1989). Rather, the statute grants the right to
exclude others from making and using the patented invention. Id. A patent is a
written contract between an inventor and the government.... The consideration given on the part of the inventor to the government is the disclosure of his invention.... The consideration on the part of the government
given to the patentee for such disclosure is a monopoly for seventeen years
of the invention disclosed to the extent of the claims allowed in the patent.
Amgen, Inc. v. Chugai Pharmaceutical Co., 706 F. Supp. 94, 99 (D. Mass. 1989)
(quoting Marcyan v. Nissen Corp., 578 F. Supp. 485, 498 (N.D. Ind. 1982)).
37. Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980); Kewanee Oil Co. v.
Bicron Corp., 416 U.S. 470, 480 (1974).
38. 35 U.S.C. §§ 1-376 (1988).
39. See supra note 36 (defining exclusive right).
40. 35 U.S.C. § 154 (1988). The practice in the U.S. is to reward patent
rights to the first to invent, not the first to file an application. Ihnen, supra
note 3, at 411.
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used. 41 To obtain a patent, an inventor must demonstrate that the
invention meets four basic requirements. 42 First, the invention
must pertain to patentable subject matter. 43 An inventor must also
41. See, e.g., In re Pleuddemann, 910 F.2d 823, 825-26 (Fed. Cir. 1990) ("a
single invention may be viewed legally as having three or more different
aspects").

42. See Ihnen, supra note 3, at 422-30 (how to draft biotech patent claims).
43. 35 U.S.C. § 101 (1988). The subject matter requirement ensures that
patentable subject matter includes any process, machine, manufacture, or composition of matter, or any improvement of any of these. Id. Section 101 states in

full: "Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof,
may obtain a patent therefor, subject to the conditions and requirements of this
title." Id.
The Patent Code defines "process" to be any "process, art or method, and
includes a new use of a known process, machine, manufacture, composition of
matter, or material." 35 U.S.C. § 100 (1988). A "machine" is a "mechanical device or a combination of mechanical powers and devices to perform some function and produce a certain effect or result." Corning v. Burden, 56 U.S. (15
How.) 252, 267 (1853). A "manufacture" is an article that has been changed or
transformed, resulting in a new and different character or use. Diamond v.
Chakrabarty, 447 U.S. 303, 307-08 (1980); Anheuser-Busch Brewing Ass'n v.
United States, 207 U.S. 556, 562 (1908). "Composition of matter" includes "all
compositions of two or more substances.. .and all composite articles." Diamond
v. Chakrabarty, 447 U.S. 303, 308 (1980); 1 E. LIPSCOMB'S WALKER ON PATENTS
§ 2:9 (3d ed. 1984). Abstract ideas, products and laws of nature, and physical
phenomena are not patentable. Chakrabarty,447 U.S. at 309; Parker v. Flook,
437 U.S. 584, 593 (1978); O'Reilly v. Morse, 56 U.S. (15 How.) 62, 112-13 (1853).
As for biotechnology, the patent office has issued patents for, inter alia, genes,
DNA sequences, vectors and plasmids, hybridomas, monoclonal antibodies, single-celled organisms, multicellular organisms, and the processes for obtaining
the products. Ihnen, supra note 3, at 408.
The United States Supreme Court opened the door for biotechnology patents in the case of Diamond v. Chakrabarty, 447 U.S. 303 (1980). See Ihnen,
supra note 3, at 407 (Chakrabarty "released a tremendous log jam of patent
applications" at the PTO and "assured the continued filing of large numbers of
new applications.")
The issue in Chakrabarty was whether a living organism, in that case a
genetically engineered bacterium, is patentable subject matter. Cakrabarty,
447 U.S. at 307. The genetically altered bacterium was capable of breaking
down several components of crude oil and would be useful for cleaning oil
spills. Id. at 305.
Emphasizing the broad language of section 101 of the Patent Code, the
court held that living organisms are patentable. Id. at 309. The court noted that
the broad terms in section 101, such as "manufacture" and "composition of matter," modified by "any," demonstrates that Congress intended a wide scope of
patent coverage. Id. In fact, "anything under the sun" that is human-made is
patentable. Id. at 316.
The proper focus of inquiry is whether the invention is a product of nature
or whether it is human-made. Id. at 309-10. The court discounted the argument, which the dissent advanced, that Congress could not have foreseen applying the patent laws to living organisms. Id. at 314-15. The majority noted that it
is the nature of inventions to be unforeseeable, especially 200 years in advance;
this is the reason that Congress drafted the patent laws with broad and flexible
language. Id. at 316. Any other interpretation of section 101 would undermine
the purpose of the patent laws. Id.
The dissent further argued that because there was a separate body of law
for plant patents, then there should be separate laws for living organisms. Id. at
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show that the claimed invention is useful,44 novel, 45 and nonobvi320. The dissent concluded that the court should defer the issue until the legislature has acted, and therefore the patent for the living organism should be
denied. Id. at 321-22. The majority responded that the plant acts were not
meant to limit patent protection and were not inconsistent with the patent act.
Id. at 313-14.
Since Chakrabarty,Patent and Trademark Office Board of Appeals has
held that plants are patentable subject matter outside of the plant acts. Ex
parte Hibberd, 227 U.S.P.Q (BNA) 443 (P.T.O. Bd. App. 1984).
As demonstrated in cases such as Ex parte Allen, the subject matter requirement does not pose a significant problem for those inventors seeking biotechnology patents. 2 U.S.P.Q.2d (BNA) 1425 (P.T.O. Bd. App. 1987) (nonnaturally occurring polyploid oysters are patentable subject matter); see also Ex
parte Hibberd, 227 U.S.P.Q (BNA) 443 (P.T.O. Bd. App. 1984) (plants are patentable subject matter under 35 U.S.C. § 101).
For example, one may obtain a patent for a DNA sequence if it is transposed into another cell, because that is not how the sequence naturally exists.
Armitage, supra note 26, at 49. Also, the PTO has granted a patent to Harvard
University for a genetically-engineered mouse. U.S. Patent No. 4,736,866 (1988);
SCIENCE NEWS, Apr. 16, 1988, at 244. The patent claims a genetically engineered
"transgenic nonhuman mammal." Id.
Harvard researchers isolated a gene that causes cancer in mammals and
then infected the gene into fertilized mouse eggs. N.Y. Times, Apr. 13, 1988, at
Al, col. 5. The patented animal is highly susceptible to cancer which allows for
more efficient testing of causes and cures for cancer. Id. The offspring of the
mice will have the same properties. Id.
The focus of the patentable subject matter inquiry is whether human intervention produced the claimed product and whether the claimed product occurs
naturally. Chakrabarty,447 U.S. at 309-10; Ex parte Allen, 2 U.S.P.Q.2d (BNA)
1425 (P.T.O. Bd. App. 1987) (patent denied on other grounds). Most biotechnology inventions will qualify as patentable subject matter because the inventions
are the result of human manipulation and do not exist in nature.
44. 35 U.S.C. § 101 (1988); see generally Brenner v. Manson, 383 U.S. 519
(1966). An invention must have some utility apart from research. Id. at 534-35
(if claim human therapy must demonstrate specific and substantial utility beyond laboratory).
If the invention is a process, the inventor must demonstrate that the product of that process is useful. Brenner,383 U.S. at 535; Tennessee Valley Auth. v.
Monsanto Chem. Co., 383 F.2d 973, 977 (5th Cir. 1967). Furthermore, to be considered useful under section 101, the utility of an invention must be definite and
known, rather than contingent upon some future research. In re Kirk, 376 F.2d
936, 945 (C.C.P.A. 1967).
Another aspect of the utility requirement is that the claimed invention
must have been actually made. Id. However, a court will not question whether
the product has been acceptably reduced to practice unless one skilled in the art
would have reason to question the objective truth of a claim. Ex parte Rubin, 5
U.S.P.Q.2d (BNA) 1461, 1462 (P.T.O. Bd. App. 1987) (holding that cancer treatment claims are no longer per se incredible).
The utility requirement poses special problems for biotech researchers because it may not be sufficient to demonstrate that an invention is effective in a
culture dish. The PTO may require proof that the invention is effective in vitro.
When human therapy is alleged, substantiating evidence will be required. In re
Jolles, 628 F.2d 1322, 1327 (C.C.P.A. 1980). For example, a scientist claiming a
cure for AIDS will have to demonstrate that the invention is effective for that
purpose in humans. Thus, whether the biotechnology invention has definite
and known utility outside of future research, which may be difficult to surmise
in the early stages of research, is an issue that biotechnology inventors must
overcome in order to receive patent protection for their inventions. Compare

The John Marshall Law Review

(Vol. 24:263

Jolles, 628 F.2d at 1324 (utility sufficiently shown where treatment was effective
on 53 of 100 human patients, and on lab animals) with In re Buting, 418 F.2d 540
(C.C.P.A. 1969) (utility insufficiently shown where treatment effective on only
2 types of cancer yet claimed effective for 7 types).
Also, in much of biotechnology the starting materials, such as the DNA
sequence incorporated into a vector, are not useful until they actually produce
the useful protein. Mossinghoff, supra note 8, at 311. However, courts have not
adhered to a strict interpretation of the utility requirement in these instances
thus far. Ihnen, supra note 3, at 412. For instance, the utility of intermediaries
such as DNA vectors depends upon the utility of the final product. Id. Hence,
the utility requirement hurdles are generally minimal but may prove more
challenging for some invention types.
45. 35 U.S.C. § 102 (1988). Under section 102 of the Patent Code, a patentable invention must be novel, meaning that the'claimed invention must not "exist" already. Id. Section 102 states:
A person shall be entitled to a patent unless- (a) the invention was known
or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the
applicant for patent, or (b) the invention was patented or described in a
printed publication in this or a foreign country or in public use or on sale in
this country, more than one year prior to the date of the application for
patent in the United States, or (c) he has abandoned the invention, or (d)
the invention was first patented or caused to be patented, or was the subject
of an inventor's certificate, by the applicant or his legal representatives or
assigns in a foreign country prior to the date of the application for patent in
this country on an application for patent or inventor's certificate filed more
than twelve months before the filing of the application in the United
States, or (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention
thereof by the applicant for patent, or on an international application by
another who has fulfilled the requirements of paragraphs (1), (2), and (4) of
section 371(c) of this title before the invention thereof by the applicant for
patent, or (f) he did not himself invent the subject matter sought to be patented, or (g) before the applicant's invention thereof the invention was
made in this country by another who had not abandoned, suppressed, or
concealed it. In determining priority of invention there shall be considered
not only the respective dates of conception and reduction to practice of the
invention, but also the reasonable diligence of one who was first to conceive
and last to reduce to practice, from a time prior to conception by the other.
35 U.S.C. § 102 (1988); see also Funk Bros. Seed Co. v. Kalo Inoculant Co., 333
U.S. 127, 130 (1948). All features of the claimed invention must have been disclosed in order to "anticipate" and hence invalidate the claimed invention (or
deny the patent). American Seating Co. v. National Seating Co., 586 F.2d 611,
618 (6th Cir. 1978).
A product or process is novel, for purposes of the Patent Act, as long as it is
not found in nature or other prior art in that exact form. PATENT AND TRADEMARK OFFICE, U.S. DEP'T OF COMMERCE, MANUAL OF PATENT EXAMINING PROCEDURE § 706.03(a) (5th ed. rev. 1988). The underlying rationale for this
requirement is that an inventor should not be permitted to monopolize something that the public is currently enjoying. Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
This requirement usually is met readily because most naturally-occurring
biotechnology-related products are "re-worked" to a state that is not found in
nature. See, e.g., Hormone Research v. Genentech, 708 F. Supp. 1096, 1101 (N.D.
Cal. 1988) (HGH made by Genentech structurally different from natural HGH),
aff'd, vacated, and remanded, 904 F.2d 1558 (9th Cir. 1990). Most human proteins are found in minute quantities in the human body. Consequently, if the
protein is isolated and purified, it will be distinguishable from its natural counterpart and patentable due to its purity. In re Kratz, 592 F.2d 1169 (C.C.P.A.
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ous. 46 These and other requirements pose potential problems in
their application to biotechnology. 47 However, the most ominous of
1979) (pure form of strawberry flavor not obvious) (citing In re Bergstrom &
Sjovall, 166 U.S.P.Q. (BNA) 256, 262 (C.C.P.A. 1970)). "Pure material is necessarily different from less pure or impure materials, hence 'pure' materials are
'new' with respect to them." Kratz, 592 F.2d at 1173.
Although the novelty requirement readily may be met, the PTO has two
tools it may use to deny a patent under the novelty requirement: anticipation
and the one-year statutory bar. 35 U.S.C. § 102(a) (1988). A patent claim will be
anticipated, and therefore unpatentable for lack of novelty, when all of its elements can be found in a single disclosure (description) that qualifies as prior art
under section 102. Id. § 102(a)-(b).
Because many biotechnology products are reformed versions of a naturally
occurring protein, the novelty hurdle is not as easy for biotechnology inventors
to overcome. See, e.g., Kratz, 592 F.2d at 1174 (court addressed specific problem
of patenting a product that may occur naturally). The court stated that a natural composition anticipates (and hence invalidates) an invention only if 1) the
natural composition inherently contains the naturally occurring compound, and
2) the claim broadly encompasses both the known natural composition and the
naturally occurring compound. Based upon this reasoning, the court held that
the purified form of strawberry flavor was not anticipated by the naturally occurring strawberry flavor. Id. A biotechnology inventor can avoid problems
with the anticipation issue if he or she diligently defines the differences between the invention and the prior art, including any naturally occurring versions. See, e.g., Hormone Research, 708 F. Supp. at 1101 (HGH made by
Genentech structurally different from natural HGH).
46. 35 U.S.C. § 103 (1988). See infra notes 49-61 and accompanying text
(discussing nonobvious requirements and problems the requirement poses to
biotechnology).
47. Section 112 of the patent code dictates the disclosure requirements of a
patent. 35 U.S.C. § 112 (1988). The disclosure requirements ensure that an inventor had possession of the claimed subject matter on the effective filing date
of the patent application. In re Herschler, 591 F.2d 693, 700-01 (C.C.P.A. 1979).
There are three issues within the section 112 requirement that a patent examiner or court will consider: enablement, best mode, and adequate description. 35
U.S.C. § 112 (1988).
To meet the requirement, there must be a sufficient teaching concerning
the subject matter of the claims that would enable one skilled in the pertinent
art to make and use the claimed invention. Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384 (Fed. Cir. 1986) (citing Raytheon Co. v. Roper
Corp., 724 F.2d 951, 960 (Fed. Cir. 1983)); In re Moore, 439 F.2d 1232, 1236
(C.C.P.A. 1971). The scope of the enablement should be commensurate with
the scope of the protection sought by the claims. Moore, 439 F.2d at 1236. If the
methods are known in the art, an inventor need not describe them in the patent
in order to meet the enabling requirement. In re Wands, 858 F.2d 731, 735 (Fed.
Cir. 1988).
To meet the description requirement, an inventor must provide a full,
clear, and concise description of the invention in terms that enable one skilled
in the pertinent art to make and use the invention without undue experimentation. Id. at 737; In re Moore, 439 F.2d 1232, 1236 (C.C.P.A. 1971). It is acceptable if some experimentation is still needed as long as it is not undue. Wands,
858 F.2d at 736-37; see also Hormone Research, 592 F.2d at 1115 (must show by
clear and convincing evidence that invention is not enabling, which is a question
of law as all claim interpretations are).
The inventor must also describe the best mode he or she knows for making
and using the invention. The best mode denotes the one contemplated by the
inventor at the time the application was filed. Hybritech, 802 F.2d at 1384; Kis-
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tier Instrumente AG v. United States, 203 U.S.P.Q. (BNA) 511 (Ct. Cl. Tr. Div.
1979), off'd, 628 F.2d 1303 (Ct. Cl. 1980).
One problem facing biotechnology inventors in meeting the disclosure requirements is describing how to "create" a living organism. See, e.g., Ex parte
Forman, 230 U.S.P.Q. (BNA) 546 (P.T.O. Bd. App. & Int. 1986) (inventor insufficiently disclosed how to make genetically engineered bacteria since the process
would require undue experimentation to make). Such problems are exacerbated if the starting materials are not available to the public or if undue experimentation would be necessary to make the invention. An inventor may meet
the enablement and best mode requirements by depositing the living organism
in a cell depository. Wands, 858 F.2d at 735-36. The cell depository may distribute samples of the organism once the patent issues. Id. at 735. A deposit of
the organism in a culture bank may be necessary unless the starting organism is
readily available to the public. Id. The deposited organism may be a starting
material, such as a bacteria or phage, or the final patented organism, such as the
altered microorganism with special abilities. However, depositing in a culture
bank is not always necessary to meet the enablement requirement. Id. at 736;
Ex parte Goeddel, 5 U.S.P.Q.2d (BNA) 1449, 1450 (P.T.O. Bd. App. 1987). If
recreating the organism would not require undue experimentation, then a deposit will not be required. Wands, 858 F.2d at 736. If a comprehensive and
detailed disclosure, which one skilled in the art could follow, is provided, then a
deposit will not be necessary to meet the enabling requirement. Goeddel, 5
U.S.P.Q.2d (BNA) at 1450; see also Ihnen, supra note 3, at 427 (if no novel techniques required then deposit unnecessary, but prudent).
Biotechnology inventors may overcome disclosure problems if they draft
the description of the invention, including how to make and use the invention,
with great care and detail. When microorganisms are involved in the invention,
prudence dictates that an inventor deposit several clones of the microorganism
in a culture bank. However, the deposit route may not be the best answer for
large multicellular animals, such as cows.
The one-year statutory bar also may prevent an inventor from obtaining a
patent for her invention. An inventor would be barred if the invention was in
"public use" more than one year before the inventor commenced the patent
petition. 35 U.S.C. § 102 (b) (1988). However, if the questioned use was experimental in nature, then the one year statutory bar does not apply. Minnesota
Mining & Mfg. v. Research Medical, 679 F. Supp. 1037, 1049 (D. Utah 1987).
There are limitations to the experimental use doctrine. One may only "test"
the product; one may not test the market. Id. Further, inventors should obtain
confidentiality agreements, where feasible, from those exposed to the invention. Id.
An invention may be used in the public domain for experimental purposes
for over a year and still be patentable. Id. at 571. The parameters of "public
use" are hazy: when does experimental use cross over to the public realm? An
ancient United States Supreme Court case appears to lay out the law. Egbert v.
Lippman, 104 U.S. 333, 336 (1881). To constitute public use: 1) it may be sufficient that only one of the patented articles is publicly used; 2) it may be sufficient that only one person publicly uses the invention, if the use is without
limitation, restriction, or agreement of confidentiality; and 3) these rules apply
even if the invention is, by its nature, incapable of being used where it can be
seen. Egbert, 104 U.S. at 336, quoted in Minnesota Mining & Mfg. v. Research
Medical, 679 F. Supp. 1037, 1049 (D. Utah 1987).
The court in Minnesota Mining held that surgeons using a catheter similar
to the claimed invention constituted public use. Minnesota Mining, 679 F.
Supp. at 1049. This case demonstrates how public use, by one other than the
inventor, of a device similar to the inventor's may be cited against the inventor.
Such public use has the same negative effect on patentability as public use of
the very same invention in question. In light of this prior art, the court denied
the patent application on the grounds of obviousness. Id. at 1057. The court
stated that "any non-secret use of the completed and operative invention or
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these is the section 103 nonobviousness requirement. 48
The Patent and Trademark Office ("PTO") will not grant a
patent if the subject matter of the invention, taken as a whole,
would have been obvious at the time of the invention to a person of
ordinary skill 49 in the pertinent art, such as someone with a general
understanding of the relevant science to which the invention pertains. 50 In Graham v. John Deere Company,51 the United States
Supreme Court formulated a tripartite approach to be followed
when determining whether an invention is obvious. 52 First, a trial
court or patent examiner at the PTO, whichever the case may be,
must consider the scope and content of the existing teachings in the
discovery in its natural and intended way is a public use .... Id. at 1049. The
application of this requirement to biotech is no less hazy than to other inventions.
If an inventor is careful about publicly using his or her invention, then this
aspect of the utility requirement will not impede obtaining a patent. There is
much debate concerning the conflict between the academic ethic of early disclosure and sharing research versus the patent and commercial practice of secrecy.
See generally Note, Patentand Trade Secret Protectionin University-Industry
Research Relationships in Biotechnology, 24 HARV. J. LEGIS. 191 (1987) (thorough discussion of issues involved).
48. 35 U.S.C. § 103 (1988). Section 103 states:
A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences
between the subject matter sought to be patented and the prior art are such
that the subject matter as a whole would have been obvious at the time the
invention was made to a person having ordinary skill in the art to which
said subject matter pertains. Patentability shall not be negatived by the
manner in which the invention was made. Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of
section 102 of this title, shall not preclude patentability under this section
where the subject matter and the claimed invention were, at the time the
invention was made, owned by the same person or subject to an obligation
of assignment to the same person.
35 U.S.C. § 103 (1988).
Section 103 is essentially a codification of the principals enunciated in
Hotchkiss v. Greenwood, 11 U.S. (How). 248 (1851). Graham v. John Deere Co.,
383 U.S. 1, 17 (1966).
49. This hypothetical person is assumed to be familiar with all the relevant
prior art. Orthopedic Equip. Co. v. United States, 702 F.2d 1005 (Fed. Cir. 1983).
50. 35 U.S.C. § 103 (1988); In re Sovish, 769 F.2d 738, 742 (Fed. Cir. 1985);
Orthopedic Equip. Co. v. United States, 702 F.2d 1005, 1012 (Fed. Cir. 1983). The
nonobvious inquiry is distinguishable from the novelty inquiry in that it does
not concern whether the claimed invention already exists in the prior art. Orthopedic, 702 F.2d at 1010-11. The novelty inquiry proceeds first. Id. If the
prior art discloses every claim of the invention sought to be patented, then the
patent would be denied and the nonobvious inquiry never confronted. Id.
The Federal Circuit framed the obviousness inquiry as "whether a person
of ordinary skill in the art, having all of the teachings of the references before
him, is able to produce the structure defined by the claim." Id. at 1013.
51. 383 U.S. 1 (1965).
52. Id. at 17. The approach outlined in Graham applies equally to both
product and process patents. See, e.g., Santa Fe-Pomeroy, Inc. v. P & Z Co., 569
F.2d 1084, 1091 (9th Cir. 1978) (applied Graham test in determining obviousness
of claimed process).
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sciences relevant to the invention ("prior art"). 53 Second, the differences between the prior art and what the inventor claims as his
or her invention must be determined. Third, the level of ordinary
skill in the pertinent art must be assessed. 54 In making an obviousness determination, an examining court must view the claimed
invention as a whole,5 5 and avoid using hindsight.5
Additionally, the trial court or examiner must examine secondary considerations if present. 57 For example, evidence of a long
felt need for the invention and the failure of others to discover the
remedy would tend to prove that the invention was nonobvious.5 s
The commercial success of the invention and copying by others
demonstrate that the invention may not have been obvious. 59 Generating unexpected results should favor a finding that the invention
was nonobvious. 60
53. Graham, 383 U.S. at 17. The "scope of prior art" refers to any references that are reasonably pertinent to the particular problem that the invention
addresses. Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1535 (Fed. Cir.
1983). Sources of pertinent art include publications, common knowledge in the
pertinent field, prior patents, and foreign patents. Id.
54. Graham, 383 U.S. at 17. There are several factors a court or patent examiner may consider in determining the "level of ordinary skill" in the art: 1)
the education level of the inventor; 2) the type of problems encountered in the
art; 3) prior solutions to those problems; 4) the rapidity with which innovations
are made; 5) the sophistication of the technology; and 6) the education level of
persons in the art. Environmental Designs, Ltd. v. Union Oil Co., 713 F.2d 693,
696 (Fed. Cir. 1983), cert. denied, 464 U.S. 1043 (1984).
55. Loctite Corp. v. Ultraseal Ltd., 781 F.2d 861, 874-75 (Fed. Cir. 1985). As
discussed infra note 141 and accompanying text, the Durden court improperly
applied the rule of considering the invention as a whole. See Bender, Griffen &
Lipsey, PatentDecisions of the United States Court of Appeals for the Federal
Circuit The Year 1985 in Review, 35 AM. U.L. REV. 995, 1005 (1986).
56. W.L. Gore & Assoc. v. Garlock, Inc., 721 F.2d 1540, 1556-57 (Fed. Cir.
1983).
57. Graham, 383 U.S. at 17; see also Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1380 (Fed. Cir. 1986) (secondary considerations must be
considered before obviousness decision reached); Cable Elec. Prods. v.
Genmark, Inc., 770 F.2d 1015, 1026 (Fed. Cir. 1985) (court must examine secondary considerations); Perkin-Elmer Corp. v. Computervision Corp., 732 F.2d
888, 895 (Fed. Cir. 1984) (evidence of secondary considerations support a conclusion of nonobviousness), cert. denied, 469 U.S. 857 (1984); Stratoflex, Inc. v.
Aeroquip Corp., 713 F.2d 1530, 1538 (Fed. Cir. 1983) (if present, court must examine secondary considerations).
58. Graham, 383 U.S. at 17-18.
59. In Hybridtech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367 (1986),
the claimant was seeking a patent for improving diagnostic kits for diseases. Id.
at 1368-70. The court looked at the commercial success of these diagnostic kits
as a determinative factor in allowing the claim. Id. at 1382. The court found
that a doubling of sales in one year, from 6.9 million to 14.5 million, of one of the
kits, and a 25% market share another kit obtained as a market leader, were
important facts showing the nonobviousness of the kits. Id.
60. Id. at 1382. The Hybritech court found that the claimed invention "unexpectedly solved longstanding problems." Id. For example, the diagnostic kits
performed with a higher degree of accuracy and fewer false positives when de-

19No]

Biotechnology Patent Protection Act

In contrast to the United States' 200-year-old patent law,6 1 biotechnology truly has prospered only in the last decade. 62 A significant biotechnology achievement involves the production of rare
human proteins, such as insulin, in quantities accessible to millions
of patients. 6 3 Other advances include the development of alpha interferon,64 human growth hormone ("HGH"),65 and an accurate
means for the detection of cancer. 66
A large part of biotechnology consists of isolating a gene sequence 6 7 that codes for a desired protein, and then transforming
that gene sequence so that it will produce a protein in large, usable
quantities.6 Today there are two standard procedures that dominate biotechnology research. 69 The first is genetic engineering, or
recombinant technology. Molecular biologists have developed ways
to transfer human genes, which are composed of DNA, into the
DNA of bacteria. 70 The resulting bacteria will produce the human
tecting problems. Id. at 1383; see also Perkin-Elmer,732 F.2d at 894 (determining obviousness involves a factual inquiry into unexpected results).
61. 35 U.S.C. §§ 1-376 (1989).
62. For an excellent discussion of the history of biotechnology, see Amgen,
Inc. v. Chugai Pharmaceutical Co., 13 U.S.P.Q.2d (BNA) 1737 (D. Mass. 1990)
(in depth discussion of principals of genetic engineering); see generally J. ELKINGTON, THE GENE FACTORY 15-41 (1985) (background and history of biotech).
63. Insulin is used to treat diabetes. M. STRICKBERGER, GENETICS 167 (3d
ed. 1985) In diabetics, sugar levels that the hormone insulin normally control
are not properly regulated. Id. The administration of insulin protects diabetics
from possible coma and death. Id. at 168.
Genetic engineering has allowed the production of insulin for treatment of
diabetes in humans. Researchers have isolated genes that contribute to diabetes
in their search for a cure for the disease. Atchison & MacLaren, What Causes
Diabetes, 263 Sci. AM. 62, 68 (July 1990).
64. Alpha interferon is helpful in treating some cancers and other viruses
by controlling the proliferation of dangerous cells. ELKINGTON, supra note 62,
at 39.
65. HGH promotes body growth, fat mobilization, and inhibition of glucose
oxidation. STEDMAN'S MEDICAL DICTIONARY 1302 (24th ed. 1976).
66. One biopharmaceutical company, Immunomedics, has developed a colon
cancer detection method that is expected to be approved for the U.S. market.
PR Newswire, May 24, 1990. The detection kit, based upon monoclonal antibodies, can detect minute cancers smaller than can be seen by x-rays. Id.
67. Deoxyribonucleic acid (DNA), the "molecule of life," resides on chromosomes in sequences which are found in the nucleus of every cell of a eucaryotic organism. RECOMBINANT DNA, supra note 5, at 6-8.

68.

ELKINGTON,

supra note 62, at 24-25. In protein synthesis, RNA trans-

ports genetic information from the DNA to cytoplasm, where protein production occurs. RECOMBINANT DNA, supra note 5, at 32-37 & 49-50; see also Crick,
Barnett, Brenner & Watts-Tobin, GeneralNature of the Genetic Codefor Proteins, 192 NATURE 1227 (1961).
69. Armitage, supra note 25, at 54-55. For a discussion of these two procedures, see infra notes 70-77 and accompanying text.
70. Armitage, supra note 25, at 55. Vectors are used for cloning foreign
genes. RECOMBINANT DNA, supra note 5, at 67-68 & 189-97. Plasmids, a type of
vector, are autonomously replicating "minichromosomes" that are circular and
often mobile. Id. at 24.
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protein coded for by the human DNA. 71 Scientists use these recombinant proteins to create new drugs for the treatment of deficien72
cies in humans.
The second basic procedure in biotechnology concerns isolating
and purifying monoclonal antibodies. 73 Antibodies are key ele-

ments in the human immune system and are used to develop vac-

cines. 74 The antibodies are termed monoclonal because they have
75
been cloned from a single, isolated and purified antibody.
Monoclonal antibodies are used for the accurate and quick detection
of cancer, viruses, and other antigenic substances.7" By the 1990's,
these two processes have become well-known to molecular biologists, and their use is widespread.7 7 Because the biotechnology industry employs these "old" processes to create new products, the
nonobvious requirement of section 103 often proves an insurmountable hurdle to obtaining patent rights.78 The PTO has in fact de79
nied process patents on this basis.
71. See

RECOMBINANT

DNA, supra note 5, at 9 (each protein and enzyme

has a single corresponding gene).

72. See generally Barkstrom, Recombinant DNA and the Regulation of Biotechnology: Reflections on the Asilomar Conference, Ten Years After, 19 AKRON L. REV. 81, 81-87 (1985) (recounting history and description of genetic

engineering).
73. An antibody is a disease fighting compound found in the body. ELKINGTON, suPra note 62, at 28. The immune system responds to pathogens such
as a bacterium or virus by producing antibodies. Id. For a detailed discussion of
the genetic research on the AIDS virus, see Mills & Masur, AIDS-Related Infections, 263 Sci. AM. 50 (August 1990).
74. RECOMBINANT DNA, supra note 5, at 117-24; ELKINGTON, supra note 62,

at 28.
75. ELKINGTON, supra note 62, at 29. Purifying a culture, usually blood or
urine, that contains many antibodies to retrieve the specific antibody needed
was virtually impossible ten years ago. Id. However, today's advances permit
scientists to create an extremely pure antibody solution. Id.
76. Id.; see, e.g., Stagnaro-Green, Detection of At-Risk Pregnancy by Means
of Highly Sensitive Assays for Thyroid Antibodies, 11 J. AM. MED. A. 1422
(1990) (study showing efficacy of immunoassays in detecting at-risk
pregnancies).
77. As researchers well know, retrieving a gene sequence is an arduous task
requiring years of labor to accomplish. See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co., 706 F. Supp. 94 (D. Mass. 1989) (EPO took many years to develop).
78. See supra note 48 (citing 35 U.S.C. § 103 (1988)).
79. See IBA STATEMENT, supra note 8, at 4-6 (IBA conducted survey at Patent Office regarding Durden rejections of biotech claims). The IBA concluded
that the application of Durden has had a chilling effect on the biotechnology
industry. Id. at 6; see also Graham v. John Deere Co., 383 U.S. 1, 25 (1966).
Some biotechnology inventions have been disqualified from patent protection
because retrieving the gene would be obvious due to the fact that the method of
retrieval is well-known and because certain properties of the protein may be
known in the relevant art. See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co.,
706 F. Supp. 94 (D. Mass. 1989) (process and product patents denied as obvious
where recombinant DNA technology well-known in art and where product already disclosed in prior art).
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Inadequacies in U.S. trade laws are also problematic to the biotechnology industry. The first Congress passed the Tariff Act of
July 4, 1789 to encourage and protect manufacturers.s ° Since then,
Congress has amended and supplemented the Act with over 200
statutes."' Congress recently amended section 337 of the Tariff Act
s
of 193082 to extend protection to process patents.8
Unfortunately,
the amendment does not cover the importation of a product made
overseas from a patented starting material. s 4 This oversight opens
the door for unfair trade practices.ss
Because patent rights are key incentives to researchers, the
present deficiency in patent protection will be detrimental to biotechnology advancement. Therefore, legislative action is necessary
to eliminate, effectively and promptly, patent disincentives currently at work.
III.

INADEQUACIES IN U.S. LAWS IN PROTECTING BIOTECHNOLOGY

AND THE EFFICACY OF THE

A.

BPPA

Denial of Patent Protectionfor Processes Involving
Nonobvious Starting Materialsand Final Products

The PTO grants patents for new and useful processes and useful improvements thereof.s6 A process is a series of steps that leads
to a useful result.8 7 The scope of a process patent is more limited
than that of a product patent in that process patent protection extends only to the specific process claimed, while product patent protection encompasses the product and its use and sale, regardless of
80. Speech by E. Re, Chief Judge of the United States Customs Court, International Bar Association Conference (Nov. 3, 1977), cited in Litigation
before the United States Customs Court, 19 U.S.C.A. XVII (1978). Congress has
the power to regulate commerce with foreign nations. U.S. CONST. art. I, § 8.
Further, a State cannot impose imposts or duties on imports or exports without
the consent of Congress. U.S. CONST. art. I, § 10.
81. E. Re, supra note 80.
82. 19 U.S.C.A. § 1337 (1989).
83. The ITC has the power to issue a temporary exclusion order if it has
reason to believe a violation exists. Id. § 1337(e). It can issue a permanent exclusion order upon finding a section 1337 violation. Id. § 1337(d). Also, the ITC
can issue a cease and desist order against anyone violating or believed to be
violating section 1337. Id. § 1337(f).
84. See, e.g., Amgen, Inc. v. International Trade Comm'n, 902 F.2d 1532
(Fed. Cir. 1990).
85. See, e.g., id. (Congress did not even consider this issue in debating the
BPPA); 4 F.J.S. 1001 (1986).
86. 35 U.S.C. § 101 (1988); see also Cochrane v. Deener, 94 U.S. 780 (1877).
87. 2 D. CHISUM, PATENTS § 1.03 (1990). "A process is a mode of treatment
of certain materials to produce a given result. It is an act, or a series of acts,
performed upon the subject-matter to be transformed and reduced to a different state or thing." Id. (quoting Cochrane, 94 U.S. at 780).
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how and by whom it is manufactured.ss Process patents must meet
the same requirements of utility, novelty, nonobviousness, and patentable subject matter, as do other utility patents. However, the
section 103 nonobvious requirement is threatening to become an insurmountable obstacle for biotechnology researchers seeking process patents. The confused status of the law renders process patent
protection for biotechnology processes questionable at best.
1.

The Importance of Process PatentProtection

Process patents are a significant form of protection for several
reasons.8 9 First, U.S. law prohibits the importation into the U.S. of
goods that have been "produced, processed, or mined under or by
means of a process covered by the claims" of an unexpired U.S. patent. 9° Similar protection results from the expansion of the definition of infringement to include the importation of a product made
abroad using a patented process. 91 Process patents may be crucial
because certain foreign jurisdictions do not recognize product patents for pharmaceuticals but recognize process patents for making
pharmaceuticals. 92
Second, the additional protection of a process patent 93 would
encourage a more complete disclosure of an invention, such as
describing the process by which the starting materials interact most
efficiently. 94 Some commentators have expressed a fear that grant88. Amgen, Inc. v. Chugai Pharmacuetical Co., 706 F. Supp. 94, 103 (D.
Mass. 1989) (citing United States v. Studiengesellschaft Kohle, 670 F.2d 1122,

1127 (D.C. Cir. 1981)).
89. See Murashige, Section 102/103 Issues in Biotechnology PatentProsecution, 16 AM. INTELL. PRop. L.A.Q.J. 294, 309-10 (1988-89) (outlining reasons for
importance).
90. Tariff Act of 1930, 19 U.S.C. § 1337(a) (1988) (as amended in 1988); see
also Certain Indomethacin, Inv. No. 337-TA-183 (1986). If the ITC determines
that there has been a violation of section 337, then it may issue an exclusion
order or cease and desist order. Swecker, US. ITC Law Is Amended to
Strengthen Section 337Protection,3 EUR. INTELL. PROP. REv. 95,95 (1989). The
penalty for violating an exclusion order is $100,000 per day or the value of the
goods, whichever is greater. Id.
Other amendments to the Tariff Act include, inter alia: the complainant
need not show the efficient operation of manufacture in the U.S., and the com-

plainant need not show economic injury if it is a process patent that is being
infringed. Id. A plaintiff must show only that the importation of an item is an
unfair trade practice. 35 U.S.C. § 1337(a)(1)(B) (1988).
91. Omnibus Trade and Competitiveness Act, 35 U.S.C. § 154 (1988) (as
amended in 1981); see also 35 U.S.C. § 271(g) (1988) (defines infringement as
importation into or use or sale within the U.S. of a product made by a process
patented in the U.S.).
92. Murashige, supra note 89, at 310. Such restrictions still exist in China,
most of the Eastern bloc, and South America, although it is on its way out. Id.

93. This is in addition to patents covering starting materials and final
products.

94. In re Mancy, 499 F.2d 1289, 1294 (C.C.P.A. 1974) (increased knowledge

of discovery and access to new starting material serves public interest); In re
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ing a process patent in addition to a product patent unjustifiably
augments an inventor's exclusive rights; however, this type of pat95
ent protection exists already under section 271 of the Patent Code.
Thus a process patent will not be a significant extension of already
existing patent rights.96
Third, the granting of process patents will reduce the incidence
of "inventing around" patented starting materials. In the biotechnology field, it is relatively easy to modify patented starting materials to circumvent existing patent claims.97 Possessing a process
patent would allow a biotechnology inventor to block this sort of
unfair practice. Finally, the added protection will eliminate unfair
trade practices currently in operation that allow a company to manufacture abroad and import to the U.S. a product, often in the form
of a drug or pharmaceutical, derived from patented starting
materials.
2. Current Law on Process Patents
The present law on process patents for claims based on new
starting materials used in old processes offers little guidance to attorneys and inventors. The Patent Code does not address the issue
specifically, and the case law is disconsonant. 98 The confusion
originates from several early decisions of the Court of Customs and
Patent Appeals ("CCPA") that held that the mere existence or use,
Kuehl, 475 F.2d 658, 666-67 (C.C.P.A. 1973) (disclosure increases "wealth of
technical knowledge"). But see 2 D. CHisuM, PATENTS § 5.04(8) (1990). Professor Chisum questions whether method of use claims will necessarily "significantly increase" quality of disclosure, especially where the use is obvious. Id.
§ 5.04(8), at 5-361. He notes that some disclosure is already required to meet the
section 101 utility requirement. Id. § 5.04(8), at 5-361 n.13.
95. 35 U.S.C. § 271 (1988); Bender, Griffen & Lipsey, Patent Decisions of
the U.S. Court of Appeals for the FederalCircuit: The Year 1985 in Review, 35
AM. U.L. REV. 995, 1005 (1986); see, e.g., Kuehl, 475 F.2d at 666 (granting process
patents does not materially increase scope of protection which already includes
right to exclude others from making, using, or selling the claimed composition).
The possibility that double patenting may result may be eliminated by terminal disclaimers. 2 M. ADELMAN, PATENT LAW PERSPECTIVES § 2.8(5), at 79293 (1990).
96. But see D. CHISUM, supra note 94, § 5.04(8), at 5-365 (discussing situations where process patent may provide additional protection).
97. IBA STATEMENT, supra note 8, at 2. For example, a scientist may use:
1) a different phage to transport the genetic information; or 2) different enzymes to splice the genetic information; or 3) a different host cell to manufacture the recombinant protein; or 4) the patented sequence attached to
additional genetic information. See Daily Report for Executive (BNA) A-2
(Feb. 8, 1990) (quoting Sen. Boucher).
98. The subjective nature of a section 103 obviousness inquiry worsens the
situation. Wiseman, Biotechnology Patent Practice: A Primer, 3 AM. INTELL.
PRop. L.A.Q.J. 394, 409 (1988-89); see also In re Durden, 763 F.2d 1406, 1411
(Fed. Cir. 1985) (section 103 inquiry unpredictable and must be done on case-bycase basis).
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in an otherwise obvious process, of novel and nonobvious starting
materials is insufficient to render that process patentable. 99 In
these cases, the PTO and courts assumed that the applicant's disclosure of the new material could be used to determine the obviousness of the process incorporating or resulting in the material. 1° °
In other words, these courts deemed the new starting materials or
the final product part of the prior art for purposes of a section 103
inquiry for the claimed process.
A later line of precedent emerged that observed a more liberal
standard. The CCPA in In re Kuehl 10 1 allowed patents for old
processes that employed new and nonobvious starting materials if
their use in that process would not have been obvious to one skilled
in the art. 10 2 This and subsequent opinions emphasized the impropriety of considering the new material as part of the prior art when
03
making a section 103 determination for the process.'
According to the Kuehl court, the focus of a section 103 inquiry
should be whether it would have been obvious to one of ordinary
skill in the art to use the nonobvious starting material to achieve
the final product. 1° 4 The court abolished the practice of considering
99. For cases discussing the insufficiency of existence or use of novel or
nonobvious starting materials, in an otherwise obvious process, to render the
process patentable, see generally In re Neugebauer, 330 F.2d 353 (C.C.P.A.
1964); In re Albertson, 332 F.2d 379 (C.C.P.A. 1964); In re Hoeksema, 399 F.2d
269 (C.C.P.A. 1968); In re Kanter, 399 F.2d 249 (C.C.P.A. 1968); In re Larsen, 292
F.2d 531 (C.C.P.A. 1961); In re Saunders, 154 F.2d 693 (C.C.P.A. 1946); Ex parte
Wagner, 88 U.S.P.Q. (BNA) 217 (P.T.O. Bd. App. 1950).
100. See D. CHISUM, supra note 94, § 5.04(8), at 5-360 (courts used inventor's
teachings of new material in obviousness determination).
101. 475 F.2d 658 (C.C.P.A 1973) (opinion by Giles Rich, J., with Markey,
Almond, Baldwin, and Lane, J.J., joining).
102. The court in Kuehl upheld the patentability of a conventional process
that employed a novel starting material and resulted in a novel product. Id.
The applicant in Kuehl obtained a patent for a novel zeolite, ZK-22, but the
PTO rejected his process claim for using ZK-22 to crack hydrocarbons. Id. at
660. The examiner based the rejection on a prior art reference that disclosed
the cracking of hydrocarbons using another class of zeolites, and the applicant's
failure to show unexpected results using ZK-22. Id. at 660.
See In re Kerkoven, 626 F.2d 846 (C.C.P.A. 1980) (reversed section 103 rejection); In re Richman, 563 F.2d 1026 (C.C.P.A. 1977); In re Werthheim, 541
F.2d 257 (C.C.P.A. 1976) (reversed section 103 rejection), later proceeding,646
F.2d 527 (C.C.P.A. 1981); In re Way, 514 F.2d 1057 (C.C.P.A. 1975); In re Wadlinger, 496 F.2d 1200 (C.C.P.A. 1974); In re Geerdes, 491 F.2d 1260 (C.C.P.A. 1974)
(reversed section 103 rejection); In re Schneider, 481 F.2d 1350 (C.C.P.A. 1973)
(reversed section 103 rejection).
103. The Kuehl court stated that In re Saunders, 154 F.2d 693 (C.C.P.A.
1946); In re Larsen, 292 F.2d 531 (C.C.P.A. 1961); and In re Albertson, 332 F.2d
379 (C.C.P.A. 1964) were inconsistent with section 103 standards in that the
courts considered the properties of the compound to determine the obviousness
of the process. Kuehl, 475 F.2d at 665. Thus, Kuehl effectively overruled Saunders. D. CHISUM, supra note 94, § 5.04(8), at 5-360.
104. Kuehl, 475 F.2d at 663.
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the new starting material as prior art for purposes of this inquiry. 05
Specifically, the court in Kuehl found that, although it was known
that zeolites were useful in cracking hydrocarbons, because the
properties of a newly discovered zeolite would not have been
1°
known, its use for the cracking of hydrocarbons was not obvious. 6
The logical extension of Kuehl is that if the starting materials
are nonobvious, as determined by the PTO or a court, then the process employing the starting materials is necessarily nonobvious.
However, the court avoided laying down a general rule and limited
its holding to the fact pattern before it.10 7
Much later, in In re Durden,l08 the Federal Circuit, without
stating so, regressed to the previous approach of considering any
new materials as prior art in a section 103 inquiry concering the
claimed process. 1° 9 As a result, a more stringent nonobviousness
standard has re-emerged, thwarting attempts to obtain process
patents.110
The issue in Durden was whether a chemical process, otherwise obvious, was patentable because either or both the specific
starting material employed and the final product obtained is novel
and nonobvious."
The Federal Circuit affirmed the PTO's rejec105. Id. at 662. The court quoted In re Prater, 415 F.2d 1393, 1393 (C.C.P.A.
1969), for the proposition that an invention "should be considered as part of 'the
subject matter as a whole' and not part of the prior art." Id. (emphasis in

original).
106. Id. at 663. The court noted that ZK-22 was not a "homologue, isomer, or
chemical analogue" of the prior art zeolites and pointed to two undisputed differences between ZK-22 and the prior art class of zeolites. Id. at 663. The court
distinguished In re Albertson, 332 F.2d 379 (C.C.P.A. 1964), because the claimed
(and rejected) process in that case involved the use of a common reducing agent
to reduce the new and patented compound to create the new and patented reduced version of the compound. Id. at 665-66. While the invention in Kuehl
involved the properties tied to the use of a new catalyst. Id.
107. Id. at 661-62 (court refused as too broad applicant's proposed rule that
allowance of composition claims necessarily entitles applicant to patent for
method of using composition).
108. 763 F.2d 1406 (Fed. Cir. 1985) (Rich, J., wrote the opinion with Markey
and Nichols, J.J., joiniAg).
109. PATENT LAW PERSPECTIVES § 2-796.1 (1989). The Durden court asserted
that Kuehl was readily distinguishable from the facts in Durden. Durden, 763
F.2d at 1410. The process in Kuehl involved cracking hydrocarbons using a
novel catalyst. Id. Presumably, a chemist of ordinary skill would not have predicted this cracking. Whereas the process in Durden supposedly would have
been obvious (and predictable) to a chemist of ordinary skill. See id.
110. See, e.g., Ex parte Kifer, 5 U.S.P.Q.2d (BNA) 1904 (P.T.O. Bd. App. 1987)
(roof flashing process obvious despite use of nonobvious starting material); Ex
parte Goodall, 231 U.S.P.Q. (BNA) 831 (P.T.O. Bd. App. 1985).
111. Durden, 763 F.2d at 1408. In Durden the inventor obtained patents for
the starting materials, novel oxime compounds, and the final product when
these were reacted, novel carbamate compounds. Id. at 1407. The PTO based its
rejection on cited prior art that involved the same process completed with similar reactants. Id. (PTO cited Punja, U.S. Patent No. 3,843,669). The Punja process and the Durden process both involved reacting an oxime group to form a
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tion of the process claim.'1 2 The court reasoned that the nonobviousness and novelty of starting materials and final products do not
13
necessarily render an otherwise conventional process patentable.
The court distinguished Kuehl, explaining that the process of
concern in Kuehl was not predictable on the basis of "mere possession" of the novel starting material, while in Durden, the outcome4
of the process as applied to the novel compound was predictable."
The court found the facts before it indistinguishable from the i facts
6
in a 1964 case," 5 which involved the same reduction process." It
appears that the similarity of the fact patterns explains the otherwise superficial distinction."17 Finally, the Durden court also declined the opportunity to announce a general rule, holding only for
the specific facts before it." 8
carbamate ester. Id. at 1408. The compounds in Punja and Durden differed in
structure in that the Punja compound was a 5-member ring and the Durden
compound was a 6-member ring, and the location of the carbonyl groups differed. Id. Durden argued that the starting materials in the invention differed
from those in the prior art. Id. However, Durden failed to show how these
differences result in a product other than what one of ordinary skill in the relevant art would expect. Id. The PTO noted, and the Federal Circuit agreed, that
the result of the claimed process using patented starting materials would have
been obvious to a chemist of ordinary skill. Id. at 410.
112. Durden, 763 F.2d at 1407.
113. Id. at 1410. The court stated that the case was indistinguishable from In
re Albertson, 332 F.2d 379 (C.C.P.A. 1964). Id. at 1409. In Albertson, the starting materials used and the product produced by the claimed process were novel
and nonobvious; however the process claims were rejected as obvious in view of
references demonstrating the same chemical process applied to other materials.
Albertson, 332 F.2d at 382. The court noted that while a process might be new it
is not necessarily nonobvious. Durden, 763 F.2d at 1410 (a process may become
new with the use of new starting materials, however, this new process may be
the expected result of what is done).
The dissent in the lower court Durden decision argued that Albertson was
no longer "viable" after a contrary decision in In re Kuehl, 475 F.2d 658
(C.C.P.A. 1973). Durden, 763 F.2d at 1410. The majority below disagreed, and
simply distinguished Durden from Kuehl. Id.
114. Id. at 1410.
115. In re Albertson, 332 F.2d 379 (C.C.P.A. 1964).
116. The court in Albertson held that the use of nonobvious starting material
will not render a process nonobvious. Id. The claimed process involved reducing a new starting material to produce a new final product, both of which claims
were allowed. Id. at 380.
117. For a discussion of why it would be improper to rely on Albertson, see
infra notes 139-40 and accompanying text.
118. The court stated:
We are sure that there are those who would like to have us state some clear
general rule by which all cases of this nature could be decided. Some
judges might be tempted to try it. But the question of obviousness under
section 103 arises in such an unpredictable variety of ways and in such different forms that it would be an indiscreet thing to do. Today's rule would
be likely regretted in tomorrow's case.
Durden, 763 F.2d at 1411. Unfortunately, it is the Durden ruling that is so
regrettable.
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The Dui-den decision is especially threatening to biotechnology,
where there exist but a few indispensable processes by which an
inventor may produce recombinant proteins.'1 9 In fact, the PTO
often cites Durden in its rejection of biotechnology process
claims. 120 For example, several issues in Amgen, Incorporated v.
Chugai PharmaceuticalCompany 12 1 spring from the PTO's rejection of process patent claims based on Durden. The PTO rejected
Amgen's claim for a process of manufacturing recombinant EPO
23
("rEPO") i 22 using Amgen's patented starting materials.1
Very recently the Federal Circuit analyzed the scope of Durden in In re Pleuddemann.'24 The Pleuddemann court reversed
the PTO's rejection of the applicant's process claims.1 25 The court
distinguished Durden and found that the case was factually apposite to Kuehl. 26 The applicant's processes related to bonding
27
materials and priming surfaces using newly patented compounds.1
119. See supra notes 70-77 and accompanying text (discussing standard procedures used in biotechnology). The genius of biotechnology is the application
of known processes (e.g., genetic engineering), to create new inventions (e.g.,
recombinant protein). One method is immunoassay, which determines the
presence or amount of antigen in body fluids by employing the ability of an
antibody to recognize and bind to an antigen. Hybritech, Inc. v. Monoclonal
Antibodies, Inc., 802 F.2d 1367, 1369 (Fed. Cir. 1986), cert denied, 480 U.S. 947
(1987).
120. IBA STATEMENT, supra note 8, at 4-6; see, e.g., Amgen, Inc. v. Chugai
Pharmaceutical Co., 706 F. Supp. 94, 110 (D. Mass. 1989) (PTO rejected process
involving recombinant DNA technology under authority of Durden). A court
may refer to either or both of the following to reject a process patent: 1) prior
art concerning the recombinant or immunoassay technology, and 2) general
knowledge in the pertinent art of the properties of the desired protein, or final
product. Id. In Ex parte Goodall, 231 U.S.P.Q. (BNA) 831 (P.T.O. Bd. App.
1986), the Board held that even if the applicant's hybridoma and antibody products were patentable, the patentability of the related processes would be in
question in light of Durden. Id. at 831.
121. 13 U.S.P.Q.2d (BNA) 1737 (D. Mass. 1989); see also Amgen, Inc. v.
United States Int'l Trade Comm'n, 902 F.2d 1532 (Fed. Cir. 1990); Anmgen, Inc. v.
Chugai Pharmaceutical Co., 706 F. Supp. 94 (D. Mass. 1989).
122. Amgen did not obtain a patent for the resulting rEPO because purified
EPO had already been patented by Genetics Institute. Amgen, 13 U.S.P.Q.2d
(BNA) at 1739. It is a fundamental concept in patent law that product patent
protection is not limited by the process used to manufacture the product.
Amgen, 706 F. Supp. at 104. It is the equivalence of the product's ingredients
and the substantial similarity of the proportions of those ingredients to another
product that determines infringement. Id.
123. Amgen, 706 F. Supp. at 109 (discussing but not analyzing rejection based
upon Durden). The patented starting materials include a purified gene sequence, the sequence transformed into a vector, and the host cell transfected
with the genetic sequence. Id. at 95.
124. 910 F.2d 823 (Fed. Cir. 1990) (Rich, J., again wrote the opinion, which
Friedman and Mills, J.J., joined).
125. Id. The PTO based its rejection on Kuehl. Id. at 825.
126. Id. at 827.
127. Id. at 824. The applicant sought a patent for a process for bonding a
polimerizable material to a mineral filler and a method for priming a surface to
improve its bonding to certain organic resins. Id.
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The same process involving similar compounds was well known in
the art.128

In Pleuddemann, the court noted that when making a section
103 determination, the prior art does not include the applicant's
new teachings, i.e., the properties of the new starting materials or
final product. Unfortunately, the court refused to acknowledge
that this was the flaw in Durden.129 Instead, the court asserted that
the "real difference" between Durden and Kuehl resides in the fact
that the process in Durden was a method of making while the process in Kuehl was a method of using.I' ° As discussed in Part IV of
this comment, this distinction is superficial and unsatisfactory because, inter alia,it may be manipulated with skillful claim drafting.
3. Durden Should Be Overruled in Favor of a General Rule
As demonstrated in the previous section, the Durden decision
further obfuscated an already confused state of law. Unless a reliable and consistent standard to determine the obviousness of a process is fashioned, the future of biotechnology developments may be
compromised. 13' There is evidence that Durden has had a chilling
effect on biotechnology process patent applications. 32 Because biotechnology research involves the use of known processes to create
new products, Durden seriously threatens the attainability of biotechnology process patents.'"
128. Id. at 825.
129. Pleuddemann,910 F.2d at 828.
130. Id. at 827. The court categorized Kanter and Neugebauer as process of
making claims as well. Id. The Industrial Biotechnology Association ("IBA")
concluded that Pleuddemann "offers no improvement in the current situation
IBA STATEMENT, supra note 8, at 7.
for biotechnology ....
131. 136 CONG. REc. E213 (daily ed. Feb. 7, 1990) (statement of Rep.
Boucher).
132. IBA STATEMENT, supra note 8, at 6. Based on Kuehl, the PTO routinely
rejects certain claims such as those concerning the production of proteins or of
monoclonal antibodies. Murashige, supra note 89, at 310.
The IBA conducted an independent search at the Patent Office to determine the impact of the Durden decision on biotech patent applications. IBA
STATEMENT, supra note 8, at 5. The IBA found that where product patents had
issued but related process patents had been abandoned, 60% of the abandonments were linked to Durden, and 40% were dropped after interviews with the
PTO. Id. Where process claims were issued, two-thirds of these applicants had
to overcome initial Durden rejections; Durden was not at issue in the remaining
one-third. Id. at 6. These and additional facts led the IBA to the conclusion
that the PTO has applied Durden inconsistently and that Durden has had a
chilling effect on the biotech industry. Id. at 5 & 6. The use of Durden is on the
upswing. Wiseman, Biotechnology Patent Practice: A Primer,16 AM. INTELL.
PROP. L.A.Q.J. 394, 410 (1988-89).
133. See supra notes 70-77 and accompanying text (most biotech process patents revolve around recombinant DNA or monoclonal antibody immunoassay
technologies).
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Moreover, courts and the PTO have misapplied the decision, 134
while other courts have distinguished or limited Durden's application. 135 Commentators have been critical of the decision.'3s In
short, the Durden decision is an anomaly, rendering the case law
inconsistent and uninstructional. As one commentator noted, this
issue should be resolved once and for all so that the judiciary may
13 7
focus its resources on more compelling issues.
It is apparent that Durden was wrongly decided. The Durden
court improperly considered the properties of the new starting
materials and final product in determining whether the process involving these compounds was obvious. 138 This approach was forbidden in Kuehl, and continues to be proscribed. 1 39 Durden must be
overruled either by legislative action or with an en banc decision of
the Federal Circuit. 14°
The proposed BPPA would overrule Durden by providing that
a process does not fail for obviousness as long as an essential start141
ing material used in the process is both novel and nonobvious.
This provision is not contrary to the protection and purpose of section 103.
134. See In re Pleuddemann, 910 F.2d 823 (Fed. Cir. 1990) (court reversed
PTO's rejection based on Durden); In re Dillon, 892 F.2d 1554 (Fed. Cir. 1989)
(court held that PTO's reliance on Durden misplaced), vacated and rev'd on
other grounds on reh'g, 919 F.2d 688 (Fed. Cir. 1990).
135. See Procter & Gamble v. Nabisco, 11 U.S.P.Q.2d (BNA) 1241, 1254 (D.
Del. 1989) ("Durden may properly be viewed as only requiring an overall inquiry into the obviousness of a method or process claim...").
136. See Murashige, supra note 89, at 312 (holding in Durden "clearly aberrant"); PATENT LAW PERSPECTIVES § 2-795 (1989) (describing Durden as a "disappointing" decision); IBA STATEMENT, supra note 8, at 4 ("[v]irtually all legal
commentators and practitioners have concluded that Durden was wrongly decided and is applied in a fashion that wrongly denies process patent
protection").
137. PATENT LAw PERSPECTIVES § 2-792 (1989). The author noted that, since
similar exclusive rights already inhere in the product patent, making the fine
distinctions in cases such as Durden to determine whether a process is obvious,
notwithstanding the obviousness of the relevant compound, is a waste of judicial resources. Id.
138. Id. § 2-796.1.
139. The Durden court obviously relied on Albertson, Neugebauer, and
Kanter in reaching its decision. However, these three cases were decided before
Kuehl, which proscribed this approach.
140. An opportunity presented itself in the en banc rehearing of In re Dillon,
892 F.2d 802 (Fed. Cir. 1989), where a three judge panel distinguished Durden
and held that the claimed process was patentable. The Federal Circuit, rather
than overrule Durden, weakened it by stating that the newness or obviousness
of a starting material is just another factor in determining the obviousness of a
claimed process. However, the new Dillon decision is unlikely to alleviate the
deterious influence Durden has on biotech process patents.
141. H.R. 3957 § 1, 101st Cong., 2d Sess., 136 CONG. REC. E207 & E213 (daily
ed. Feb. 7, 1990).
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This provision of the BPPA will facilitate the obtaining of process patents in biotechnology. Molecular biologists using recombinant technology to develop new starting materials that produce
useful proteins' 42 will obtain adequate protection of the use of these
starting materials. 143 Because courts have been reluctant to adopt a
similar per se rule, 144 it is necessary for Congress to intervene.
The BPPA will not be a panacea for all of biotechnology's woes,
and may create its own problems. For example, complications may
arise when multiple patents issue that cover the same general process. Also, license arrangements may become more complex, perhaps allowing a patent holder to impose additional fees for the use
of a process. Further, courts have cautioned that, based on this reasoning, even simple processes such as heating and dissolving, may
be patented if performed on a new material. 145 However, this possibility is minimized because such processes must still meet the novelty and utility requirements of sections 101 and 102 of the Patent
146
Code.
B. Importance of Intellectual PropertyProtection World-Wide
Protection of intellectual property is crucial to U.S. international competitiveness and trade performance in the field of biotechnology.' 47 U.S. pharmaceutical companies lose hundreds of
millions of dollars each year as a result of inadequate protection of
their patented products. 14 Measures are being taken world-wide,
as well as in the U.S., to gain the protection biotechnology-related
products need and deserve. 149 Unfortunately, there currently ex142. The protein may be patentable by way of its purity, or the protein may
have been purified previously--and patented-so that the junior inventor will
not get a patent for the final product, but only the process of making it. In re
Kuehl, 475 F.2d 658 (C.C.P.A. 1973).
143. 136 CONG. REC. E207 (daily ed. Feb. 7, 1990) (statement of Sen. Moorhead). The bill would help U.S. biotech companies to achieve "parity" with international competitors that obtain similar process patents in their home
countries. Id.
144. See In re Albertson, 332 F.2d 379, 381 (C.C.P.A. 1964); In re Larsen, 292
F.2d 531, 533 (C.C.P.A. 1961).
145. See In re Albertson, 332 F.2d 379, 382 (C.C.P.A. 1964); In re Durden, 763
F.2d 1406, 1410 (Fed. Cir. 1985) (quoting Albertson).
146. See 35 U.S.C.A. §§ 101-102 (1989); see also supra notes 45-46 (discussing
novelty and utility requirements).
147. Winter, The Role of the United States Government in Improving InternationalIntellectual Property Protection,2 J. L. & TECH. 325 (1987).
148. Mossinghoff, supra note 8, at 308 (citing Pharmaceutical Manufacturers
Association study).
149. See generally Griffen, Exporting Biotechnology: The Pitfalls, 3 AM. INTELL. PROP. L.A.Q.J. 542 (1988-89) (analyzing various export regulation); Fuller,
Intellectual Property Rights Associated with Biotechnology: An International
Trade Perspective, 3 AM. INTELL. PROP. L.A.Q.J. 529 (1988-89) (discussing various types of biotech inventions and protections available). The U.S. is involved
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ists a serious "loophole" in the United States' intellectual property
15 0
laws.
While Congress has bolstered process patent protection, 15 1 the
trade laws do not extend protection to patented starting materials.1 5 2 Although the ITC may exclude from importation products
made using patented processes, the ITC does not have jurisdiction
to exclude a product that is made with a U.S. patented starting material.153 In other words, the ITC cannot exclude goods that are
derived from patented biotechnology products unless the process of
making the final product is patented. 154 The Federal Circuit held
that when amending the trade laws to cover process patents, Congress did not consider the possibility of protecting starting materials, thus it would be improper for a court to extend such
protection. 155
in: 1) negotiations of a Draft Treaty on the Harmonization of Certain Provisions in Laws for the Protection of Inventions; 2) an exchange program of patent examiners with foreign patent offices; and 3) establishing minimum patent
standards through the General Agreement on Tariffs and Trade (GATT). Address of Quigg, 38 PAT. TRADEMARK & COPYRIGHT J. 467 (1989).
150. "The trade laws have got to be updated so that the [biotech] pioneers
don't take a (beating]." Legal Times, Jan. 8, 1990, at 21, col. 1 (quoting Stephan
Lawton, Amgen lobbyist).
151. See supra notes 82-84 and accompanying text (describing new laws concerning protection of processes). The law amending 35 U.S.C. § 1335 overruled
the Supreme Court's holding in Deepsouth Packing Co. v. Laitram Corp., 406
U.S. 518, 527 (1972), where the court held that it is not an infringement under
section 271 to make or use a patented product outside of the United States. In
that case the court noted that a "clear and certain signal" from Congress is necessary before courts will expand patent protections. Id. at 531.
152. In one recent case, the applicant, arguing that the 1988 process amendment extended protection to starting materials, cited language from prior interpretations of section 337 of the Trade Act such that section 337 proscribed
"manufactur[ing] abroad by a process which, if practiced in the United States,
would infringe" a United States patent. In re Certain Recombinant Erythropoietin, 10 U.S.P.Q.2d (BNA) 1906, 1909 (U.S. I.T.C. 1989) (the applicant was
Amgen, Inc.), vacated on other grounds sub nom. Amgen, Inc. v. United States
Int'l Trade Comm'n, 902 F.2d 1532 (Fed. Cir. 1990) (Federal Circuit affirmed
holding of no protection for starting materials but reversed ITC's dismissal for
lack of jurisdiction-dismissal should have been on the merits). The ITC responded that it did not intend to suggest that section 337 covers the use abroad
of a process using a patented article. Id. at 1539.
153. Amgen, Inc. v. United States Int'l Trade Comm'n, 902 F.2d 1532 (Fed.
Cir. 1990).
154. 136 CONG. REC. E213 (daily ed. Feb. 7, 1990) (statement of Rep.
Boucher). Amgen, Inc., argued that patent protection for a host cell necessarily
covered the intracellular processes, such as the production of rEPO. Amgen,
902 F.2d at 1534. Thus, such host cells should be deemed processes for purposes
of 35 U.S.C. § 1337. Id.at 1537. The Federal Circuit, analogizing a host cell with
a machine, rejected this argument. Id. at 1537-38.
155. Amgen, 902 F.2d at 1539-40. The court indicated that Congress should
resolve the problem. Id. Amgen had referred the court to the legislative history for the 1988 amendment to protect process patents: "[Tihe continued broad
jurisdiction of the International Trade Commission will help U.S. industry address the unfair activity of foreign competitors who, for example, import prod-
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The inability on the part of the ITC to protect patented starting
materials is one of the many issues raised in the litigation of Amgen,
Incorporatedv. Chugai PharmaceuticalCompany' 56 over the right
to use and manufacture rEPO. Genetics Institute ("GI") owns the
patent covering the purified, 157 "natural" form of EPO.1
However, Amgen has the patent for the starting materials, including the
genetic sequence that codes for rEPO. 159 Thus, neither party may
manufacture EPO without infringing the other's patent. 16°
Chugai Pharmaceutical Company of Japan ("Chugai"), is the
exclusive licensee of the GI patent and has manufactured rEPO in
Japan using Amgen's patented host cells; Chugai has imported the
final product to the primed U.S. market.1 1 Whereas GI's production of rEPO, under the tradename Marogen, infringes Amgen's
patent, Chugai's production abroad and subsequent importation of
Marogen does not infringe because section 271 does not cover
materials manufactured outside of the U.S. using patented starting
materials. 162 Also, the United States Code does not grant the ITC
jurisdiction to prevent Chugai from importing Marogen. 163 This
policy is inequitable and tantamount to unfair trade practices.
The BPPA will protect biotechnology companies that manufacture their products in the U.S. from similar unfair trade practices in
ucts manufactured using patented genetic engineering technology." Id. at 1539
(quoting statement of Sen. Lautenberg).
156. 706 F. Supp. 94 (D. Mass. 1989); see also Amgen, Inc. v. United States
Int'l Trade Comm'n, 902 F.2d 1532 (Fed. Cir. 1990); Amgen, Inc. v. Chugai Pharmaceutical Co., 706 F. Supp. 94 (D. Mass. 1989); Amgen, Inc. v. Chugai Pharmaceutical Co., 11 U.S.P.Q.2d (BNA) 1466 (D. Mass. 1989); In re Certain
Recombinant Erythropoietin, 10 U.S.P.Q.2d (BNA) 1906 (D. Mass. 1989).
157. GI purified the protein based on natural EPO, while Amgen purified
EPO by means of genetic engineering. Legal Times, Jan. 8, 1990, at 21, cols. 3-4.
The purified protein is the commercially valuable form. Id.
158. Amgen, 706 F. Supp. at 94. Natural in this sense means that the protein
was taken from its natural source and then purified. This is a very inefficient
method of obtaining a protein and its uses are limited.
159. Id. The starting materials that Amgen has patented include the host
cell that winds up expressing for the production of large quantities of EPO.
Legal Times, Jan. 8, 1990, at 21, cols. 3-4. Amgen lost its argument that it also
has process patent rights to the process of making EPO through recombinant
technology. Id. Amgen's EPO product, Epogen, accounts for 89% of Amgen's
revenues. Los Angeles Times, June 3, 1990, Business Section, at 1, col. 5.
160. "Put simply, Amgen cloned the stuff, but couldn't purify it. Genetics
Institute purified the protein; won the first patent on the isolated, pure, homogeneous molecule; but lost the race to clone it." Legal Times, Jan. 8, 1990, at 21,
cols. 3-4.
161. The magistrate determined that Chugai's use of host cells to produce
rEPO comes within the scope of Amgen's patent. Amgen, 13 U.S.P.Q.2d (BNA)
at 1779-80. Chugai has entered into a joint venture with Upjohn to sell the EPO
product, Marogen. Los Angeles Times, June 3, 1990, Business Section, at 1, col.
5. Sales are pending FDA clearance. Id.
162. 35 U.S.C. § 271 (1988).
163. 19 U.S.C.A. § 1337 (1989).
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two ways. 164 First, the BPPA will empower the ITC to exclude the
importation of products made using a patented biotechnological material.165 Second, the BPPA will make it an act of infringement to
166
import products made abroad using patented starting materials.
The BPPA will not put U.S. biotechnology companies at an advantage, but merely will allow them to compete on a level playing
field. In short, all products sold in the U.S.-including previously
exempt imports--will have to respect all U.S. patents. 167 American
companies will no longer have to compete with foreign companies
who have appropriated patented information without permission.
The BPPA will serve to remedy the inequities confronting U.S. biotechnology companies. As a matter of simple fairness Congress
should enact this provision of the BPPA.
The BPPA will stimulate research and development in the biotechnolgy industry. However, it is not clear why similar import
8
protection should not extend to all patented starting materials.16
While the need for protection in biotechnology is more urgent, similar protection would be valuable to those in other industries, such
as chemistry. In addition, the futures of other sciences may reveal
unexpected potential for new products or new cures to diseases. It
would be wise to protect such future developments from unfair use

as well.
IV.

ALTERNATIVE APPROACHES TO THE

BPPA

If Congress does not pass the BPPA, several viable alternatives
are available. However, none of the alternatives would be as efficacious as the enactment of the BPPA.
164. H.R. 3957, 101st Cong., 2d Sess., 136 CONG. REc. E207 & E213 (daily ed.
Feb. 7, 1990) (statements by Sen. Moorhead and Rep. Boucher, respectively).
The BPPA also amends 35 U.S.C. § 271(h) to grant district courts jurisdiction
over infringement involving importation. H.R. 3957 § 2(b)(1) (1990).
165. H.R. 3957 § 2(a) (1990).
166. H.R. 3957 § 2(b)(1) (1990).
167. 136 CONG. REC. E207 (daily ed. Feb. 7, 1990) (statement of Sen.
Moorhead).
168. "It is not a function of the patent system to favor or disfavor particular
technologies." Transgenic Animal Patent Reform Act of 1989: Hearings on
H.R. 1556 Before the Subcommittee on Courts, Intellectual Property and the
Administration of Justice, 91-92 (1989) (statements of Donald Chisum). Professor Chisum noted that the neutrality of the patent system (i.e., by not making
specific exclusions or exceptions for a particular technology) has played a significant role in its success. Id.
The IBA has no objection to expanding this provision to include all starting
materials. IBA STATEMENT, supra note 8, at 9. The IBA, however, noted that
legislation enacted to benefit a specific industry is not necessarily unfair. Id.
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Durden Is Distinguishablefrom Biotechnology Inventions

The reasoning in Durden may be distinguished from biotechnology related claims in two ways. For instance, the Durden holding appears to apply only to defined chemical reactions. 169 Because
biotechnology processes typically are not analyzed as defined chemical reactions, the Durden rationale is inapplicable. Further, courts
may distinguish Durden in that the rationale of Durden is inapplicable to biotechnology processes, because, at least at this stage of
biotechnological development, scientists have not unraveled the
170
precise processes relating to many biotechnological phenomena.
Based upon current technology, scientists cannot determine the
function of a DNA sequence until the sequence has been isolated
properly. Only at this point does it become potentially "obvious"
that incorporating this sequence into the proper process will produce the expected results. However, even at this juncture, a molecular biologist would not be able to predict what the sequence will do
given only the nucleotide sequence, or chemical composition. Genetic technology has not advanced to this level of sophistication.
In effect, too much hindsight is necessary to make the jump
that a given genetic sequence will code for a given protein. For this
reason a court may readily distinguish the Durden case, which apparently concerns predictability on a precise chemical level. Perhaps once genetic technology attains the level whereby scientists
can predict the function of a genetic sequence based upon its chemical composition, then the Durden reasoning will be applicable.
However, the Kuehl line of cases adapts much better to biotechnology process claims.
The Kuehl reasoning mandates that the novel starting materials used in the claimed process should not be considered in a section
169. Murashige, supra note 89, at 311. But see Ex parte Kifer, 5 U.S.P.Q.2d
(BNA) 1904, 1906 (P.T.O. Bd. App. 1987) (Durden is not limited to chemical
cases).
170. Rejections of biotech claims based on Durden may have been reasoned
in the following manner. All genetic sequences, which are composed of a limited variety of chemicals, are deemed one "class" of compounds. Then, because
it is known that when genetic sequences are incorporated into a new host cell,
the result is that the sequence will code for and produce its requisite protein,
the process may be deemed obvious and not patentable. In simplified terms, it
is obvious that a genetic sequence will code for a protein.
However, these simplifications demonstrate that the Durden reasoning as
applied to biotechnology is flawed. First, many genetic sequences do not code
for anything at all (e.g., introns, improperly or randomly isolated sequences, or
sequences containing a stop signal). Second, given a random sequence of DNA,
it is impossible, at least as technology exists today, to determine what the sequence will do. It may code for a protein. More likely, the sequence is "nonsense" and does not code for anything. To compare the predictable chemical
processes at issue in Durden with the complex processes involved in protein
synthesis is inane.
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103 prior art inquiry. Thus, without considering the properties of
the new DNA sequence it would be impossible to predict the outcome of using that sequence in a known biotechnology process. The
level of technology is such that it is impossible to predict the function of a genetic sequence. 171 Thus, based on the Kuehl rationale, in
biotechnology when a starting material is novel and nonobvious, its
use in an otherwise obvious process would be novel and nonobvious. 1 72 Therefore, if necessary, a patent applicant should urge that
the reasoning in Kuehl applies, and that the Durden rationale does
not.
B.

Secondary Considerations

The existence of secondary considerations such as the long felt
need for the invention, the failure of others to discover a remedy,
commercial success of the invention, unexpected results, and copying by others favor a finding of nonobviousness. 173 As an example,
in Hybritech, Inc. v. Monoclonal Antibodies, Inc.,174 the claimed
process concerned the use of monoclonal antibodies in a conventional process usually performed with polyclonal antibodies. 175 The
court, in upholding the validity of the process patent, based its holding in large part on the patentee's showing of commercial success
76
and unexpected results.1
By showing that his or her invention has generated secondary
considerations, an inventor may avoid an obviousness rejection.
However, when the patentability of an invention is still being disputed at the PTO, it may be too early for the invention to have generated any secondary considerations.
C.

Claim Drafting

Recently, courts and the PTO have been characterizing
171. In contrast, chemists may predict chemical reactions based upon the
chemical components of a compound.
172. Accord In re Mancy, 499 F.2d 1289 (C.C.P.A. 1974). The Mancy court
held that an otherwise obvious process for producing an antibiotic using a new
microorganism was patentable. Id. at 1290. The court noted that the only way
the process could be deemed obvious would be by using, improperly, the applicant's very own disclosures concerning the new microorganism. Id. at 1293.
173. Graham v. John Deere Co., 383 U.S. 1, 17 (1965); see also Hybritech, Inc.
v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1380 (Fed. Cir. 1986), cert. denied,

480 U.S. 947 (1987). But see Merges, CommercialSuccess and PatentStandards:
Economic Perspectives on Innovation, 76 CAL. L. REv. 805 (1988) (criticizing
increased importance Federal Circuit has given to secondary considerations).
174. 802 F.2d 1367 (Fed. Cir. 1986).
175. Id.
176. Id. at 1382-83.
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processes as either methods of using or methods of making. 177 The
78
former they hold are patentable, the latter are not.1
An inventor may avoid Durden rejections by characterizing the
process claims as a method of using a new material, rather than a
method of making a new material. For example, when claims involve novel DNA sequences, vectors, or host cells, it would be better to claim the method of using these starting materials, as opposed
to claiming a method of making a protein (albeit using the new
starting materials).
V.

CONCLUSION

In view of the tremendous economic and social benefits biotechnology has to offer, in addition to the incentive of staying ahead
of international competitors, Congress' priorities should be to advance progress in the biotechnology sciences. Increased patent protection is one available means to promote biotechnology
development. The Biotechnology Patent Protection Act, by increasing patent protection, would serve this end.
Congress should pass this Act because the Act would: 1) eliminate confusion regarding the application of the section 103 nonobvious requirements to process patents; 2) allow patents for known
processes that employ novel and nonobvious starting materials; and
3) by prohibiting the importation of products manufactured with
177. See In re Pleuddemann, 910 F.2d 823 (Fed. Cir. 1990). The Pleuddemann court asserted that the "real difference" between Durden and Kuehl
resides in the fact that the process in Durden was a method of making while

the process in Kuehl was a method of using. Id. at 827; see also In re Dillon, 892
F.2d 1554, 1570 (Fed. Cir. 1989) (distinguishable from Durden because facts concerned method of use of new material, while Durden concerned method of
making new material), vacated and rev'd on other grounds on reh'g, 919 F.2d
688 (Fed. Cir. 1990). Wiseman, Biotechnology PatentPractice: A Primer,3 AM.
INTELL. PROP. L.A.Q.J. 394, 410 (1988-89). Mr. Wisemann, a supervisory patent
examiner at the PTO, states that in analyzing biotech process claims, an examiner must decide whether the claim falls within the facts of Durden and Larsen
or of Kuehl and Mancy. Id. Then the examiner tellingly explains that under
the first pair of cases, a certain biotech process would have been obvious, but
not obvious under the second pair. Id. Such reasoning is erroneous, and painfully demonstrates the problems Durden instigated. An invention is obvious or
it is not. The prior art has not changed, thus it is a mystery how the outcome
can change. This underscores the importance of claim drafting to avoid phraseology that may connect the process with the Durden case.
178. Plueddemann, 910 F.2d at 827. The confusion created in making this
distinction is evident in this case. The court appears to confuse the issue, or was
not careful in its word choice. It quotes the following excerpt: "[I]n our view it
is in the public interest to permit appellant to claim the process (of use) as well
as the product... to encourage a more detailed disclosure of the specific methods of using the novel composition ..... " Id. at 826 (quoting In re Kuehl, 475
F.2d 658, 666 (C.C.P.A. 1973)) (emphasis added). Because the court's decision
was based upon the fact that the claimed process was a method of using new
starting materials, the court probably did not intend "product" to mean final
product, but rather as the startink material compounds.
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starting materials patented in the United States, prevent unfair
trade practices that hurt U.S. biotechnology companies. In sum, the
Act will stimulate and encourage biotechnology advancement by
providing needed and deserved protection for biotechnology
advancements.
Kerin Kelly

